

Article

Capturing the Kidney Transcriptome by Urinary Extracellular Vesicles—From Pre-Analytical Obstacles to Biomarker Research

Karina Barreiro^{1,2}, Om Prakash Dwivedi¹, Antti Rannikko^{3,4}, Harry Holthöfer^{1,5}, Tiinamaija Tuomi^{1,6,7,8}, Per-Henrik Groop^{7,9,10,11} and Maija Puhka^{1,2,*} 

- ¹ Institute for Molecular Medicine Finland FIMM, HiLIFE, University of Helsinki, 00290 Helsinki, Finland; karina.barreiro@helsinki.fi (K.B.); om.dwivedi@helsinki.fi (O.P.D.); harry.holthofer@helsinki.fi (H.H.); tiinamaija.tuomi@hus.fi (T.T.)
- ² Institute for Molecular Medicine Finland FIMM, EV and HiPREP Core, University of Helsinki, 00290 Helsinki, Finland
- ³ Research Program in Systems Oncology, Faculty of Medicine, University of Helsinki, 00290 Helsinki, Finland; antti.rannikko@hus.fi
- ⁴ Department of Urology, University of Helsinki, Helsinki University Hospital, 00290 Helsinki, Finland
- ⁵ III Department of Medicine, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany
- ⁶ Lund University Diabetes Centre, Department of Clinical Sciences, Lund University, 214 28 Malmö, Sweden
- ⁷ Folkhälsan Institute of Genetics, Folkhälsan Research Center, 00290 Helsinki, Finland; per-henrik.groop@helsinki.fi
- ⁸ Endocrinology, Abdominal Centre, Helsinki University Hospital, 00029 Helsinki, Finland
- ⁹ Department of Nephrology, University of Helsinki, Helsinki University Hospital, 00290 Helsinki, Finland
- ¹⁰ Research Program for Clinical and Molecular Metabolism, Faculty of Medicine, University of Helsinki, 00290 Helsinki, Finland
- ¹¹ Department of Diabetes, Central Clinical School, Monash University, Melbourne, VIC 3800, Australia
- * Correspondence: maija.puhka@helsinki.fi; Tel.: +358-400826846



Citation: Barreiro, K.; Dwivedi, O.P.; Rannikko, A.; Holthöfer, H.; Tuomi, T.; Groop, P.-H.; Puhka, M. Capturing the Kidney Transcriptome by Urinary Extracellular Vesicles—From Pre-Analytical Obstacles to Biomarker Research. *Genes* **2023**, *14*, 1415. <https://doi.org/10.3390/genes14071415>

Academic Editor: Carlo Maria Di Liegro

Received: 26 May 2023

Revised: 30 June 2023

Accepted: 6 July 2023

Published: 8 July 2023



Copyright: © 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

Abstract: Urinary extracellular vesicles (uEV) hold non-invasive RNA biomarkers for genitourinary tract diseases. However, missing knowledge about reference genes and effects of preanalytical choices hinder biomarker studies. We aimed to assess how preanalytical variables (urine storage temperature, isolation workflow) affect diabetic kidney disease (DKD)—linked miRNAs or kidney—linked miRNAs and mRNAs (kidney-RNAs) in uEV isolates and to discover stable reference mRNAs across diverse uEV datasets. We studied nine raw and normalized sequencing datasets including healthy controls and individuals with prostate cancer or type 1 diabetes with or without albuminuria. We focused on kidney-RNAs reviewing literature for DKD-linked miRNAs from kidney tissue, cell culture and uEV/urine experiments. RNAs were analyzed by expression heatmaps, hierarchical clustering and selecting stable mRNAs with normalized counts (>200) and minimal coefficient of variation. Kidney-RNAs were decreased after urine storage at -20°C vs. -80°C . Isolation workflows captured kidney-RNAs with different efficiencies. Ultracentrifugation captured DKD-linked miRNAs that separated healthy and diabetic macroalbuminuria groups. Eleven mRNAs were stably expressed across the datasets. Hence, pre-analytical choices had variable effects on kidney-RNAs—analyzing kidney-RNAs complemented global correlation, which could fade differences in some relevant RNAs. Replicating prior DKD-marker results and discovery of candidate reference mRNAs encourages further uEV biomarker studies.

Keywords: urinary extracellular vesicles; exosomes; urine; diabetic kidney disease; reference genes; miRNA; mRNA; sequencing

1. Introduction

Extracellular vesicles (EV) are nowadays a hot topic in the biomarker research field [1–4]. Urinary EV (uEV) are of particular interest for pathologies of the genitourinary tract [5–8]. Specifically for diabetic kidney disease (DKD), a microvascular complication of diabetes,

uEV are a promising source of non-invasive biomarkers [9–11] that might complement, reduce the need for or eventually even replace kidney biopsies and facilitate early diagnostics and prognosis.

Currently, effort is put on research and to set forth recommendations for uEV work, e.g., in sample handling, storage, uEV isolation and reporting [12–18]. This is highly important because there are vast differences in the pre-analytical, analytical and reporting procedures. For example, a recent survey by the Spanish Society for Research and Innovation (Spain) in Extracellular Vesicles (GEIVEX) found that the variability of preanalytical procedures can be as high as 94% [18]. Without some level of standardization, the biomarker discovery results are seldom highly robust or reproducible [19].

More specifically, one of the most pressing problem in the preanalytical part is that many collections in laboratories and biobanks may not be handled and stored optimally for uEV research. Moreover, only few studies have characterized the effect of pre-analytical variables on the uEV, especially regarding the end-point biomolecular level used in biomarker studies, e.g., the transcriptome [14]. Equally, only a few studies have comprehensively characterized the effect of EV isolation methods on transcriptomics [13,15,16,20–22]. Thus, it is difficult to compare results between dissimilar studies.

Urinary EV capture kidney transcriptome and proteome ([7,9,23–26]. With focus on uEV RNAs, we and others have shown that uEV can capture the dysregulation of RNAs associated with pathological mechanisms of DKD such as oxidative stress [9], fibrosis [27], and inflammation [28]. We have previously shown by RNA sequencing technologies that some preanalytical variables such as urine storage temperature and isolation methods affect the uEV RNA yield and global miRNA and mRNA profiles [9,14]. However, for kidney research, it would be important to understand how exactly the pre-analytical choices affect the uEV as a “liquid kidney biopsy”. Are all the uEV miRNAs and mRNAs—highly or specifically expressed by the kidney and from different disease mechanism pathways—affected by the different preanalytical variables and to which extent? Are the kidney derived RNAs for example missing completely or just downregulated and therefore still available as biomarkers?

Urinary EV reference genes represent another unmet need in the EV field. Both research on EV reference genes and recommendations on how to select the reference genes are increasing [29,30]. However, only a moderate number of sequencing datasets are currently available for rigorous search of robust reference genes that would be stable across studies, at least for uEV. Again, the effect of preanalytical variables, or demographic and disease status variables, on the stability of reference genes is not clear. This represents a problem for qPCR validation experiments. GAPDH is commonly utilized to normalize gene expression but does not work equally fine for all tissues, biofluids, or disease status [31–33]. In conclusion, it is unclear how candidate markers reported by different studies could be replicated under different experimental conditions.

In this study, we assessed the effect of storage temperature and uEV isolation workflows on uEV transcriptome by focusing on highly expressed miRNAs and enriched genes of the kidney. We assessed the replicability of previously described candidate miRNA markers of DKD and explored the existence of reference genes across diverse uEV sequencing datasets.

2. Methods

2.1. miRNA and mRNA Sequencing Datasets

The datasets included in this study were retrieved from previous publications from our group describing the pre-analytical and analytical parts including quality control in detail [6,9,13,14]. Details for each dataset are included in Table 1. For the storage temperature study, urine samples were divided in two aliquots on the collection day, and they were stored at $-20\text{ }^{\circ}\text{C}$ or $-80\text{ }^{\circ}\text{C}$ for 13–16 months. Importantly, temperature sample pairs were always stored for equal times i.e., the isolation of extracellular vesicles was done the same day. Similarly, there were no differences in the storage time for isolation workflow,

overnight (ON)/24 h collections (24 h), and pre-clearing studies between the sample pairs. Of note, except for the isolation workflow dataset, the rest of the samples were processed by ultracentrifugation.

2.2. Kidney Top Expressed miRNAs and Kidney Enriched mRNAs in uEV

Kidney enriched genes (“At least four-fold higher mRNA level in kidney compared to the average level in all other tissues”) were retrieved from The Human Protein Atlas, v20 [34,35] (www.proteinatlas.org) (accessed on 19 November 2020). For miRNAs, we used top kidney expressed miRNAs (40 miRNAs with highest expression in the kidney) which were retrieved from miRNATissueAtlas2 [36] (<https://ccb-web.cs.uni-saarland.de/tissueatlas2>) (accessed on 17 June 2022). For these analysis, raw sequencing counts were normalized as described in the original publications by using TMM (trimmed mean of M values) [37] in edgeR [38] or DEseq2 normalization [39,40].

2.3. Literature Review of miRNAs Associated with DKD

We did a literature review of miRNAs associated with DKD based on evidence from tissue (human or animal models) or in vitro models and for miRNAs based on evidence from human urine, urinary sediments or uEV (differential expression $\text{padj} < 0.05$). For the latter, some studies reported miRNAs with nominal p -values, and in such cases we included only the miRNAs that had been also validated with another quantification method or by using in-vitro or in-vivo models. To search the DKD associated miRNAs in our uEV dataset we used the reported identifiers i.e., if the literature only provided the stem identifier, we searched the immature miRNA in our dataset and not the mature miRNAs (-3p/-5p).

2.4. Stable mRNAs across Datasets

All datasets were normalized using TMM normalization. Of note, samples from overnight and 24 h collections, with and without pre-clearing and technical replicas were normalized together and we refer to this dataset as “technical dataset”. Genes with normalized counts of CPM > 200 in all samples were filtered to calculate the coefficient of variation (CV). The top 100 genes with the lowest CVs were selected from each experimental dataset and the gene lists were compared to identify shared genes across datasets. To assess the stable genes functions we used gene cards [41] (www.genecards.org) (accessed on 27 June 2023) and to assess to which pathways the stable genes contribute to, we used Uniprot knowledge base (UniProt Consortium 2023) (<https://www.uniprot.org/>) (accessed on 28 April 2023). Protein interaction was assessed using STRING V11.5 [42] (<https://string-db.org/>) (accessed on 28 April 2023).

2.5. Data Visualization

For data visualization, built-in R functions or packages ggplot2 [43], pheatmap [44], and reshape2 [45], were used. Values are represented as mean \pm SEM (standard error of the mean). Figure panels were prepared using corelDRAW 2022 v24.1.0360 (Corel Corporation, Ottawa, ON, Canada). Some of the results presented here are part of Karina Barreiro’s dissertation which is accessible in the Digital Repository of the University of Helsinki (HELDA).

Table 1. Datasets included in this study. Diabetic kidney disease (DKD), hydrostatic filtration dialysis (HFD), overnight (ON), prostate cancer (PCa), ultracentrifugation (UC), urinary extracellular vesicles (uEV), Urine Exosome Purification and RNA Isolation Midi Kit (NG). * NG was not included in the analysis due to the poor performance on RNA sequencing. ** 24 h urine collections were not pre-cleared and ON urine collections were pre-cleared.

Study	Description	Storage Temp	PI *	Pre-Clearing	Isolation Method	Urine Sample Type and Disease	n (Donors)	Analysis Type	Reference
Isolation workflows	uEV were isolated from urines	−80 °C	yes	no	UC, HFD, and NG	24 h urine samples from healthy controls and T1D patients with macroalbuminuria. All men.	healthy controls = 5 macroalbuminuria = 5	miRNA and mRNA sequencing	[13]
Storage temperature	uEV were isolated from paired urine aliquots stored at −20 °C or −80 °C.	−80 °C/−20 °C	yes	no	UC	24 h urine samples from T1D patients with normoalbuminuria, microalbuminuria or macroalbuminuria. All men.	normoalbuminuria = 2 macroalbuminuria = 2	miRNA and mRNA sequencing	[14]
DNase treatment	uEV RNA was isolated adding an in-column DNase digestion step.	−80 °C	yes	no	UC	24 h urine samples from T1D patients with normoalbuminuria, microalbuminuria or macroalbuminuria. All men.	normoalbuminuria = 11 microalbuminuria = 2 macroalbuminuria = 6	mRNA sequencing	[14]
ON/24 h	uEV were isolated from urines derived from donors that provided on the same day 24 h urine (full void during 24 h) or ON urine (full first void).	−80 °C	yes	no	UC	ON and 24 h urine samples from healthy controls and T1D patients with normoalbuminuria or macroalbuminuria. All men.	ON/24 pairs = 12	mRNA sequencing.	[9]
Pre-clearing	uEV isolated from paired urine aliquots processed +/− pre-clearing before storage.	−80 °C	yes	yes/no	UC	24 h urine samples from T1D patients with microalbuminuria or macroalbuminuria. All men.	pre-clearing pairs = 4	mRNA sequencing	[9]

Table 1. Cont.

Study	Description	Storage Temp	PI *	Pre-Clearing	Isolation Method	Urine Sample Type and Disease	n (Donors)	Analysis Type	Reference
Replicability of UC workflow	Pairs of urine aliquots were stored and processed at different time points (up to 5 months)	−80 °C	yes	no	UC	24 h urine samples from healthy controls and T1D patients. All men.	Duplicates = 6 Triplicates = 2	mRNA sequencing	[9]
DKD cohort 1	uEV isolated from urines to find candidate markers of DKD.	−80 °C	yes	yes-no **	UC	24 h or ON urine samples from T1D patients with normoalbuminuria, microalbuminuria or macroalbuminuria. All men.	normoalbuminuria = 38 microalbuminuria = 15 macroalbuminuria = 19	mRNA sequencing	[9]
DKD cohort 2	uEV isolated from urines to validate candidate markers.	−80 °C	yes	yes	UC	24 h urine samples from T1D patients with normoalbuminuria, microalbuminuria or macroalbuminuria. All women.	normoalbuminuria = 18 microalbuminuria = 8 macroalbuminuria = 4	mRNA sequencing	unpublished raw count data [9]
PCa cohort	uEV isolated from urine samples from PCa patients	−80 °C	no	yes	UC	Spot urine samples from healthy technical controls and PCa patients before and after radical prostatectomy. Men and a woman.	PCa = 3 healthy controls = 2 (1 man with 3 technical replicates and 1 woman)	mRNA sequencing	[6]

3. Results

Our study focused on the kidney-linked and putative reference RNAs in uEV isolates targeting applicability for biomarker discovery. The uEV isolates used to generate the eleven sequencing datasets analyzed in this study were comprehensively characterized in our original publications (Table 1) by electron microscopy, Western blotting, and nanoparticle tracking, RNA fragment length and protein analysis. Briefly, this quality control indicated that the main population of uEV and RNA was small in size and length (<300 nm and <300 nt, respectively) and that the presence of e.g., remnant Tamm-Horsfall protein varied, but was not extensive.

3.1. Effect of PreAnalytical Variables on Kidney Transcriptome in uEV Isolates

In previous studies we determined that some preanalytical variables such as storage temperature affect the global uEV transcriptome [13,14]. As the uEV have shown potential as “liquid kidney biopsy” [9], we now assessed whether these preanalytical variables impact the kidney transcriptome in uEV isolates. Here we analyzed the expression level of “kidney-RNAs” i.e., top kidney expressed miRNAs and kidney enriched mRNAs.

3.1.1. Effect of Storage Temperature

To analyze the effect of urine storage temperature on miRNAs that have high expression in the kidney, we focused on the top 40 kidney expressed miRNAs. In our dataset (n = 8 samples), we found 29 out of the 40 miRNAs and for 22 of those, the normalized expression level was lower in urines stored at -20°C than in urines stored at -80°C (Figure 1). Of note, two of the miRNAs were not detected at all in the -20°C samples (Table S2).




Figure 1. Effect of storage temperature on kidney top expressed miRNAs and kidney enriched genes in uEV isolates. Urine EV were isolated by UC from urine stored at -20°C vs. -80°C . (A): Heatmap depicts the expression level of 29 out of 40 top miRNAs expressed in kidney (miRNATissueAtlas2) and found in the uEV isolates (miRNAs with ≥ 1 raw count in at least 50% of the samples). (B): Heatmap depicts the expression of 33 out of 53 kidney enriched genes (human protein atlas) found in the uEV isolates (genes with ≥ 5 raw counts in at least 50% of the samples). Micro RNA (miRNA), messenger RNA (mRNA), ultracentrifugation (UC), urinary extracellular vesicles (uEV).

Out of 56 kidney enriched mRNAs we found 33 in our dataset. Analysis of the expression levels showed that 15 mRNAs were poorly represented in urines stored at -20°C compared to the ones stored at -80°C (Figure 1A). Importantly, 10 of the mRNAs were not detected at all in the -20°C samples (raw counts = 0) (Table S2).

3.1.2. Effect of Isolation Workflows

We next analyzed the effect of the EV isolation workflows on the uEV expression of kidney-RNAs. Out of 40 highly expressed miRNAs of the kidney, we found 36 in our datasets ($n = 26$ samples). All the miRNAs were stably expressed across the different isolation workflows but the expression of 18 miRNAs was lower in samples from HFD workflow (Figure 2A). We then analyzed differences in the normalized counts of these 18 miRNAs between HFD and UC samples (samples that showed low expression in HFD (4,5,6,8,9,10) and we observed that the normalized counts were systematically lower in HFD samples compared to UC, with differences ranging between 3–58%. MiRNAs with highest differences (>35%) were hsa-miR-101-3p, hsa-miR-26a-5p, hsa-miR-26b-5p, hsa-miR-27a-3p, hsa-miR-29c-3p. Regarding the kidney enriched genes, we found 31 out of the 56 and all of them had lower expression in samples from Norgen urine Exosome Purification and RNA Isolation Midi Kit (NG) (Figure 2B). Five of the mRNA were not detected in any of the NG samples (raw counts = 0) and generally, many of the samples had raw count 0 (Table S3).




Figure 2. Cont.




Figure 2. Effect of EV isolation workflows on kidney top expressed miRNAs and kidney enriched genes in uEV isolates. Urine EV were isolated by HFD, NG and UC workflows from urine samples of healthy controls ($n = 5$) and T1D patients with macroalbuminuria ($n = 5$). (A). Heatmap depicts the expression level of 36 out of 40 top miRNAs expressed in kidney (miRNATissueAtlas2) and found in the uEV isolates (miRNAs with ≥ 5 raw counts in at least 50% of the samples). (B). Heatmap depicts the expression level of 31 out of 56 kidney enriched genes (Human protein atlas) found in the uEV isolates (genes with ≥ 5 raw counts in at least 50% of the samples).

Both temperature and isolation workflow impacted the kidney transcriptome in uEV isolates and these differences are in some cases better captured by analyzing kidney-RNAs than by analyzing global expression.

3.2. Dysregulated miRNAs in Samples Stored at Suboptimal Temperature: Significance for Kidney Disease Biomarker Discovery

Previously, we reported different miRNA profiles from uEV isolated from urines stored at $-20\text{ }^{\circ}\text{C}$ vs. $-80\text{ }^{\circ}\text{C}$ [14] (from now on, for simplicity, we will refer to these samples as “urines stored at $-20\text{ }^{\circ}\text{C}$ or $-80\text{ }^{\circ}\text{C}$ ”). Specifically, by differential expression analysis of normalized counts, we found 29 downregulated and 4 upregulated uEV miRNAs in urines stored at $-20\text{ }^{\circ}\text{C}$ compared to the ones stored at $-80\text{ }^{\circ}\text{C}$. To assess the biological relevance of the dysregulated miRNAs, we performed a literature review and found that 25/33 miRNAs were associated with kidney diseases (Table 2). In addition, a careful comparison of the raw and normalized counts revealed that most of the downregulated miRNAs in urines stored at $-20\text{ }^{\circ}\text{C}$ failed to be detected (raw counts = 0), while the 4 downregulated miRNAs in urines stored at $-80\text{ }^{\circ}\text{C}$ were stably expressed across samples and had high raw counts (Tables reftabref:genes-2445271-t002 and S1). Thus, in urines stored at $-20\text{ }^{\circ}\text{C}$, a significant number of potential kidney disease markers were lost, and

the upregulated genes' raw counts were actually lower than in urines stored at $-20\text{ }^{\circ}\text{C}$. $-80\text{ }^{\circ}\text{C}$ samples.

Table 2. Down- and up-regulated miRNAs in uEV derived from urines stored at $-20\text{ }^{\circ}\text{C}$ for up to 1 year. Acute kidney injury (AKI), chronic kidney disease (CKD), diabetic kidney disease (DKD), lipopolysaccharide (LPS), streptozotocin (STZ), urinary extracellular vesicle (uEV).

ID	Raw Counts		Normalized Counts (Log2CPM)		Association with Kidney Diseases
	$-80\text{ }^{\circ}\text{C}$	$-20\text{ }^{\circ}\text{C}$	$-80\text{ }^{\circ}\text{C}$	$-20\text{ }^{\circ}\text{C}$	
hsa-miR-21-5p	42,760 ± 22,321	230 ± 115	14.5 ± 0.4	12.1 ± 0.4	Dysregulated in DKD in human tissue and DKD models [46–48].
hsa-miR-375	11,496 ± 4880	26 ± 13	12.9 ± 0.1	7.3 ± 2	Pro-apoptotic in an in vitro model of AKI (renal tubular cells) [49].
hsa-miR-192-5p	10,651 ± 5178	15 ± 8	12.7 ± 0.2	9.5 ± 0.3	Dysregulated in DKD. Associated with fibrosis [27,50,51].
hsa-miR-378a-3p	1445 ± 740	10 ± 5	9.9 ± 0.3	3.1 ± 1.6	Upregulation observed in biopsies from donors with glomerular diseases [52].
hsa-miR-101-3p	971 ± 483	0	8.6 ± 1	1.4 ± 0	Downregulated in kidneys from a mouse diabetic nephropathy model (STZ). Antifibrotic [53].
hsa-miR-107	700 ± 270	1 ± 0.3	9 ± 0.1	3.7 ± 0.8	Downregulated in kidney biopsies from allograft dysfunction [54].
hsa-miR-320b	466 ± 262	2 ± 1	8.2 ± 0.3	2.4 ± 1	
hsa-miR-345-5p	236 ± 121	0	7.2 ± 0.4	1.4 ± 0	Upregulated in urine from a chemical model of AKI in rats [55].
hsa-miR-328-3p	203 ± 88	0	7.1 ± 0.3	1.4 ± 0	Downregulated in proximal tubule cells that underwent ischemia/reperfusion [56].
hsa-miR-204-3p	202 ± 157	0	6.3 ± 0.6	1.4 ± 0	Upregulation protected podocytes exposed to high glucose from apoptosis [57].
hsa-miR-7-5p	174 ± 119	0	6.4 ± 0.7	1.4 ± 0	Downregulation protected proximal tubule cells from LPS in vitro [58].
hsa-miR-197-3p	154 ± 92	0	6 ± 0.8	1.4 ± 0	Downregulated in urine from donors with intermittent MA [59].
hsa-miR-20b-5p	151 ± 80	0	6.7 ± 0.6	1.4 ± 0	Downregulated in kidneys and cell lines from mouse models of polycystic kidney disease [60].
hsa-miR-148a-5p	133 ± 60	0	6.3 ± 0.3	1.4 ± 0	Increased in urine from donors with persistent macroalbuminuria [59].
hsa-miR-10a-3p	114 ± 79	0	5.9 ± 0.7	1.4 ± 0	Downregulated in kidneys from a mouse model of AKI [61].
hsa-miR-629-5p	109 ± 81	0	5.5 ± 0.5	1.4 ± 0	Upregulated in kidney biopsies from donors with acute tubular necrosis [62].
hsa-miR-92a-1-5p	101 ± 59	0	5 ± 0.4	1.4 ± 0	
hsa-miR-193b-3p	100 ± 62	0	5.8 ± 0.5	1.4 ± 0	Upregulated in kidney from chronic kidney disease biopsies [63].
hsa-miR-340-5p	99 ± 36	0	6.2 ± 0.3	1.4 ± 0	

Downregulated

Table 2. Cont.

	Raw Counts		Normalized Counts (Log2CPM)		Association with Kidney Diseases	
	−80 °C	−20 °C	−80 °C	−20 °C		
Downregulated	hsa-miR-3065-5p	98 ± 43	0	6.2 ± 0.3	1.4 ± 0	Upregulated in a mouse model of renal fibrosis [64].
	hsa-miR-106a-5p	92 ± 50	0	5.8 ± 0.4	1.4 ± 0	Downregulation associated with podocyte injury induced by high glucose [65].
	hsa-miR-7704	87 ± 37	0	5.8 ± 0.2	1.4 ± 0	
	hsa-miR-324-5p	74 ± 42	0	5.5 ± 0.3	1.4 ± 0	
	hsa-miR-374b-5p	60 ± 24	0	5.5 ± 0.2	1.4 ± 0	Downregulated in diabetic kidney biopsies [66].
	hsa-miR-99b-3p	59 ± 19	0	5.6 ± 0.3	1.4 ± 0	
	hsa-miR-4728-3p	59 ± 20	0	5.5 ± 0.6	1.4 ± 0	
	hsa-miR-132-3p	57 ± 12	0	5.7 ± 0.4	1.4 ± 0	Upregulation increases fibrosis in mouse and in vitro [67].
	hsa-miR-361-5p	55 ± 15	0	5.5 ± 0.6	1.4 ± 0	
	hsa-miR-664a-5p	54 ± 15	0	5.6 ± 0.3	1.4 ± 0	Upregulated in uEV from donors with Idiopathic Membranous Nephropathy [68].
upregulated	hsa-miR-10a-5p	47,380 ± 33,187	5272 ± 2636	14.4 ± 0.4	16.7 ± 0.3	Downregulated in urine of individuals with AKI [69].
	hsa-miR-125a-5p	1017 ± 399	103 ± 51	9.3 ± 0.7	12 ± 0.2	Downregulated in urine from donors with membranous nephropathy [70].
	hsa-miR-92b-3p	864 ± 413	58 ± 29	9.1 ± 0.2	11.4 ± 0.3	Upregulated in urine from donors with persistent macroalbuminuria [59].
	hsa-miR-3960	77 ± 44	15 ± 7	4.8 ± 1.1	9.4 ± 0.5	Upregulated in kidney biopsies from donors with acute tubular necrosis [62].

3.3. Replication of DKD-Associated miRNA by UC-Based uEV Isolation and Sequencing Workflow

Prior research has reported many miRNAs that associate with DKD in T1D and/or T2D. Thus, we carried out a literature search to generate a list of these DKD-linked miRNAs ($\text{padj} < 0.05$ or $p < 0.05$ and other evidence of association, see methods) and used it for studying their expression in the UC-isolated uEV from DKD patients vs. healthy controls ($n = 10$ samples). We found (i) 107 miRNAs based on evidence from tissue (human or disease models) or in vitro models and (ii) 63 miRNAs based on evidence from human urine, urinary sediments or uEV (Tables 3 and 4). MiRNAs dysregulated in tissue or in vitro models were associated to previously described DKD pathways including inflammation, fibrosis, podocyte injury, and oxidative stress (Table 3). We found 12 miRNAs in common between miRNAs deregulated in tissue or in vitro and urine/urine sediments or uEV (highlighted in bold text in Table 4), namely hsa-miR-214-3p, hsa-miR-192, hsa-miR-200c, hsa-miR-15b-5p, hsa-miR-30c-5p, hsa-miR-30b-5p, hsa-miR-21-5p, hsa-miR-30e-5p, hsa-miR-200c-3p, hsa-miR-200a-3p, hsa-miR-155-5p and hsa-miR-29b-3p, which have been shown to modulate hypertrophy, fibrosis, inflammation, and apoptosis.

Table 3. MiRNAs associated with DKD development and/or progression with evidence in kidney tissue and/or cell lines. Reported target genes for the dysregulated miRNAs have direct regulation evidence (e.g., luciferase reporter assay).

miRNA (Human)	Targeted Genes	Evidence	miRNA Regulation in Disease Group	Dysregulation Effect	Reference
let-7b-5p	Col1a2/4a1	in vitro and in vivo	Down	pro-fibrotic	[71]
miR-15b-5p	BCL-2	in vitro and in vivo	Up	pro-apoptotic	[72]
miR-16-5p	VEGFA	in vitro	Down	pro-apoptotic, podocyte injury	[73]
miR-20b-5p	SIRT7	in vitro	Up	pro-apoptotic	[74]
miR-21-5p	PTEN	in vitro and in vivo	Down	pro-fibrotic (early DKD)	[48]
miR-21-5p	PTEN	in vitro and in vivo	Up	pro-fibrotic	[46]
miR-21-5p	SMAD7	in vitro and in vivo	Up	pro-fibrotic	[47]
miR-21-5p	SMAD7	in vitro and in vivo	-	pro-fibrotic	[75]
miR-21-5p	n.d.	in vitro and in vivo	Up	anti-apoptotic	[76]
miR-21-5p	SMAD7	in vitro and in vivo	Up	pro-fibrotic	[77]
miR-21-5p	Cdc25a, Cdk6	in vitro and in vivo	Up	pro-inflammatory, pro-fibrotic	[78]
miR-21	TGF- β , SMAD7, PTEN	in vivo	Up	pro-fibrotic	[79]
miR-22	PTEN	in vitro and in vivo	Up	pro-fibrotic	[80]
miR-23a-3p	SnoN	in vitro	Up	pro-fibrotic	[81]
miR-23b-3p	HMGA2	in vitro and in vivo	Down	pro-fibrotic	[82]
miR-23b	G3BP2	in vitro and in vivo	Down	pro-fibrotic	[83]
miR-25-3p	NOX4	in vitro and in vivo	Down	oxidative stress	[84]
miR-25-3p	NOX4	in vitro and in vivo	Down		[85]
miR-25-3p	PTEN	in vitro and in vivo	Down	pro-apoptotic, increase ROS	[86]
miR-25	CDC42	in vitro and in vivo	Down	pro-fibrotic	[87]
miR-26a-5p	CTGF	in vitro and in vivo	Down	pro-fibrotic	[88]
miR-27a-3p	PPAR γ	in vitro and in vivo	Up	pro-fibrotic	[89]
miR-27a	PPAR γ	in vitro and in vivo	Up	podocyte injury	[90]

Table 3. Cont.

miRNA (Human)	Targeted Genes	Evidence	miRNA Regulation in Disease Group	Dysregulation Effect	Reference
miR-29b-3p	n.d.	in vitro and in vivo	Up		[91]
miR-29b-3p	TGF- β , SMAD3	in vitro and in vivo	Down	pro-fibrotic, pro-inflammatory	[92]
miR-29c-3p	Spry1	in vitro and in vivo	Up	pro-apoptotic, pro-fibrotic	[93]
miR-29a	HDAC	in vitro and in vivo	Down	pro-apoptotic	[94]
miR-29a	n.d.	in vitro and in vivo	Down	pro-fibrotic	[95]
miR-29a/b/c family	Col1a2/4a1	in vitro and in vivo	Down	pro-fibrotic	[96]
miR-30e-5p	GLIPR-2	in vitro and in vivo	Down	pro-fibrotic	[97]
miR-30s (family)	Mtdh	in vitro and in vivo	Down	pro-apoptotic	[98]
miR-30b-5p	SNAI1	in vitro	Down	increased markers of epithelial to mesenchymal transition.	[99]
miR-30c-5p	ROCK2	in vitro and in vivo	Down	pro-apoptotic, reduced cell proliferation, increased epithelial-mesenchymal transition	[100]
miR-34a-5p	GAS1	in vitro and in vivo	Up	regulated mesangial proliferation and glomerular hypertrophy	[101]
miR-34a-5p	SIRT1	in vitro and in vivo	Up	pro-fibrotic	[102]
miR-34c-5p	Notch1 and Jagged1	in vitro	Down	pro-apoptotic	[103]
miR-93-5p	VEGFA	in vitro and in vivo	Down	angiogenic, pro-fibrotic	[104]
miR-124-5p	n.d.	in vivo	Up	podocyte loss	[105]
hsa-miR-126-3p	n.d.	in vitro and in vivo	Up		[91]
miR-130a-3p	TNF- α	in vitro	Down	oxidative stress, pro-apoptotic	[106]
miR-130b-5p	snail	in vitro and in vivo	Down	pro-fibrotic	[107]
miR-133b	SIRT1	in vitro and in vivo	Up	pro-fibrotic	[108]
miR-134-5p	BCL2	in vitro and in vivo	Up	pro-apoptotic	[109]
miR-135a-5p	TRPC1	in vitro and in vivo	Up	pro-fibrotic	[110]
miR-140-5p	TLR4	in vitro and in vivo	Down	pro-apoptotic, pro-inflammatory	[111]

Table 3. Cont.

miRNA (Human)	Targeted Genes	Evidence	miRNA Regulation in Disease Group	Dysregulation Effect	Reference
miR-145-5p	n.d.	in vitro and in vivo	Up		[112]
miR-145-5p	Notch1	in vitro	Down	pro-apoptotic	[113]
miR-146a-5p	n.d.	in vitro and in vivo	Up	pro-inflammatory	[114]
miR-146a-5p	ErbB4, Notch1	in vitro and in vivo	Down	diabetic glomerulopathy and podocyte injury.	[115]
miR-146a	n.d.	in vivo	Down	pro-inflammatory	[116]
miR-146a	n.d.	in vitro and in vivo	Down	oxidative stress	[117]
miR-155-5p	n.d.	in vitro and in vivo	Up	pro-inflammatory	[114]
miR-155-5p	n.d.	in vitro and in vivo	Up		[91]
miR-155-5p	Sirt1	in vitro	Up	reduced autophagy, anti-fibrotic	[118]
miR-181a-5p	Egr1	in vitro and in vivo	Down	pro-fibrotic	[119]
miR-192-5p	Zeb2	in vitro and in vivo	Up	pro-fibrotic	[120]
miR-192-5p	Zeb2	in vitro and in vivo	Down	pro-fibrotic	[51]
miR-192-5p	Zeb2	in vitro and in vivo	Up	pro-fibrotic	[121]
miR-192	n.d.	in vitro and in vivo	Up in microalbuminuria, Down in macroalbuminuria		[27]
miR-192	Zeb1/2	in vitro and in vivo	Down	pro-fibrotic	[50]
miR-192	Zeb2	in vitro and in vivo	Up	pro-fibrotic	[122]
miR-193a	APOL1	in vitro	Up	Podocyte dedifferentiation	[123]
miR-195	n.d.	in vitro and in vivo	Down	anti-apoptotic	[124]
miR-196a-5p	p27(kip1)	in vitro and in vivo	Down	hypertrophy	[125]
miR-199a-3p	IKK β	in vitro and in vivo	Down	pro-apoptotic, pro-inflammatory	[126]
miR-199b-5p	SIRT1	in vitro and in vivo	Up	pro-fibrotic	[108]
miR-200a-3p	TGF- β 2	in vitro and in vivo	Down	pro-fibrotic	[127]
miR-200 b/c-3p	Zeb1	in vitro and in vivo	Up	pro-fibrotic	[121]
miR-200 b/c	FOG2	in vitro and in vivo	Up	Hypertrophy	[128]

Table 3. Cont.

miRNA (Human)	Targeted Genes	Evidence	miRNA Regulation in Disease Group	Dysregulation Effect	Reference
miR-214-3p	PTEN	in vitro and in vivo	Up	Hypertrophy	[129]
miR-214-3p	PTEN	in vitro and in vivo	Up	Hypertrophy	[130]
miR-215-5p	Zeb2	in vitro and in vivo	Down	pro-fibrotic	[51]
miR-216a-5p	PTEN	in vitro and in vivo	Up	Hypertrophy, survival	[131]
miR-216a-5p	Ybx1	in vivo	UP	pro-fibrotic	[132]
miR-217-5p	PTEN	in vitro	Up	Defective autophagy, proapoptotic	[133]
miR-217-5p	PTEN	in vitro and in vivo	Up	Hypertrophy, survival	[131]
miR-218-5p	HO-1	in vitro	Up	pro-apoptotic	[134]
miR-301a-3p	TNF- α	in vitro	Down	oxidative stress, pro-apoptotic	[106]
miR-342-3p	SOX6	in vitro and in vivo	Down	pro-fibrotic	[135]
miR-374a	MCP-1	in vitro and in vivo	Down	pro-inflammatory	[136]
miR-377-3p	SOD1/2, PAK1	in vitro and in vivo	Up	pro-fibrotic	[137]
miR-379-5p	LIN28B	in vitro and in vivo	Down	fibrotic	[138]
miR-379 megacluster	EDEM3, ATF3, TNRC6B, CPEB4, PHF21A	in vitro and in vivo	Up	pro-fibrotic	[139]
miR-423-5p	NOX4+D98	in vitro	Down	pro-apoptotic, pro-fibrotic, pro-inflammatory, oxidative stress	[140]
miR-451a	LMP7	in vitro and in vivo	Down	pro-inflammatory	[141]
miR-451a	n.d.	in vivo	Up/Down	anti-fibrotic?	[142]
miR-503	E2F3	in vitro and in vivo	Up	podocyte injury	[143]
miR-770-5p	TIMP3	in vitro and in vivo	Up	pro-apoptotic, pro-inflammatory	[144]
miR-874	LPP3	in vitro and in vivo	Up (overt nephropathy)	pro-fibrotic, anti-apoptotic	[145]
miR-874	TLR5	in vitro and in vivo	Down	pro-inflammatory	[146]
miR-1207-5p	n.d.	in vitro	Up	pro-fibrotic	[147]

Table 4. MiRNAs associated with DKD development and/or progression with evidence from urine, urinary sediments or uEV. Chronic kidney disease (CKD), diabetic kidney disease (DKD), intermittent microalbuminuria (IMA), persistent microalbuminuria (PMA), microalbuminuria (MA), type 1 diabetes (T1D), type 2 diabetes (T2D). * Validated with an independent cohort, ** validated with another detection method, in kidney biopsies, in vitro or in a model organism. MiRNAs in common with Table 3 are highlighted in bold text.

Sample	Groups	Upregulated miRNAs	Downregulated miRNAs	Reference
Urine	Urine from T1D (Normal, overt nephropathy, intermittent microalbuminuria, persistent microalbuminuria)	DKD vs. non DKD: miR-619, miR-486-3p, miR-335-5p, miR-552, miR-1912, miR-1124-3p, miR-424-5p, miR-141-3p, miR-29b-1-5p	DKD vs non-DKD: miR-221-3p	[148]
		MA vs. baseline: miR-214-3p , miR-92b-5p, miR-765, miR-429, miR-373-5p, miR-1913, miR-638	MA vs. baseline: miR-323b-5p, miR-221-3p, miR-524-5p, miR-188-3p	
		PMA vs. IMA: miR323b-5p, miR-433, miR-17-5p, miR-222-3p, 628-5p	PMA vs. IMA: miR-589-5p, miR-373-5p, miR92a-3p	
Urinary sediments	Diabetic glomerulosclerosis, minimal change nephropathy or focal glomerulosclerosis, membranous nephropathy, and healthy donors	miR-200c	miR-638, miR-192	[149]
uEV **	T1D with normoalbuminuria and microalbuminuria and non-diabetic controls	miR-130a, miR-145	miR-155, miR-424	[112]
Urine	T2D DKD, T2D, and healthy donors	miR-126 (T2D DKD > T2D)		[150]
uEV	T2D normoalbuminuric, microalbuminuric, or macroalbuminuric	microalbuminuria vs. normoalbuminuria and controls: miR-192 , miR-194, and miR-215.	macroalbuminuria vs. microalbuminuria: miR-192 , miR-215	[27]
uEV *	T2D DKD, T2D, and healthy donors	miR-320c, miR-6068		[151]
urine pellets and uEV *	T2D albuminuric, normoalbuminuric, and healthy controls	miR-15b, miR-34a, miR-636		[152]
uEV *	T2D normoalbuminuria and microalbuminuria	miR-877-3p		[153]
uEV **	T1D normoalbuminuria, intermittent macroalbuminuria, persistent macroalbuminuria, and overt macroalbuminuria	Overt vs. normal: miR-26a-1-5p, miR-30-5p PMA vs. IMA/non microalbuminuria: miR-200c-3p	Overt vs. normal: miR144-3p	[59]
Urine **		PMA vs. IMA: miR10a-5p, miR-200a-3p		
Urine *	Diabetic, DKD and healthy donors	miR-126-3p, miR-155-5p , and miR-29b-3p		[91]

Table 4. Cont.

Sample	Groups	Upregulated miRNAs	Downregulated miRNAs	Reference
Urine *	Urine and plasma from T1D and DKD		miR-30e-5p	[154]
uEV *	T2D DKD, T2D normal renal function, and non-T2D CKD	miR-21-5p	miR-30b-5p	[28]
Urine **	DKD and non-diabetic renal disease		T2D vs. non-diabetic renal disease: miR-27-3p, miR-1228	[155]
uEV *	T2D and normoalbuminuria, microalbuminuria or macroalbuminuria and healthy donors	miR-15b-5p		[72]
uEV *	TD2 DKD and healthy donors		miR-30e-3p , miR-30c-5p , miR-190a-5p, miR-98-3p, let-7a-3p, miR-30b-5p , and let-7f-1-3p	[156]

We analysed the expression levels of the miRNA from the literature review (i.e., Tables 2 and 3) in our uEV data (UC isolation workflow dataset) using expression heatmaps and checked whether the miRNAs could cluster the healthy control and macroalbuminuria groups separately by hierarchical clustering. Our uEV set showed expression of 39 out of 107 miRNAs (36%) dysregulated in DKD with evidence from tissue and in vitro studies, but they did not separate the groups (Figure 3A). However, our uEV set showed expression of a higher proportion of miRNAs—31 out of 63 (49%)—that were dysregulated in DKD with evidence from urine, urine sediment or uEV. Importantly, this set of miRNAs could divide the DKD and healthy control groups into separate clusters and this was observed both by hierarchical clustering and principal component analysis (Figure 3B,C). We focused on the miRNAs with the biggest fold changes that were located on the first and fourth (last) cluster of the heatmap in Figure 3B—they separated the groups by principal component analysis even more evidently than the 31 mRNAs (Figure 3D). From those miRNAs, we compared the direction of change between the literature review and our dataset. For the first cluster, miR-30b-5p, miR-221-3p, let-7f-1-3p, and let-7a-3p followed the same direction of change in both i.e., downregulated in DKD. In contrast, miR-15b-5p was upregulated in the literature with evidence from uEV/urine or urine sediments but downregulated in our uEV dataset. For the fourth cluster, all miRNAs (miR-424-5p, miR-486-3p, miR-335-5p, miR-126-3p) had the same direction of change than what was found in the literature i.e., upregulated in DKD. Moreover, all the miRNAs had evidence of association with DKD in vitro or in vivo and/or association with DKD pathways (in kidney or other cells) (Table 5).

To assess whether these 31 miRNAs would show some specificity for DKD, we carried a similar analysis using our uEV PCA dataset. Supporting DKD specificity, the analysis did not separate the PCA patients from healthy controls (Figure 3E).

Taken together, despite variability between experimental setups, some of the uEV/urine/urine sediment miRNAs presenting candidate markers associated with DKD in the literature were confirmed in our uEV dataset and expression level changes between experimental groups were concordant.

3.4. Exploratory Analysis of Reference mRNAs in uEV

To select the most stable mRNAs that could serve as candidate reference genes we first focused on uEV samples from our DKD studies that included men only. This choice was due to expected and higher sample-linked [9] and also biological heterogeneity in the women's cohorts. Datasets were analyzed separately to avoid batch effects i.e., isolation workflows (n = 20 samples), in-column DNase treatment (n = 19 samples), technical dataset (type of collection, pre-clearing, and replicability, see methods) (n = 39 samples), and DKD cohort 1 (T1D, men) (n = 72 samples). Of note, NG isolation workflow data and storage temperature dataset were excluded from the analysis due to the low expression level of many mRNAs (for raw counts, see Table S3). The top 100 uEV genes with the lowest CV were selected from each dataset and the genes overlapping between all of them were selected for further analysis. We found 32 uEV genes in common between the datasets (Figure 4A).

We next expanded our reference gene analysis to check the stability of expression including women's uEV samples. Here we searched genes in common between the DKD male (32 uEV stable mRNAs from first search) and DKD cohort 2 (T2D, women) (n = 30 samples) using again the top 100 uEV RNA with low CV (in cohort 2), which showed 18 mRNAs in common (Figure 4B). Finally, we assessed whether some of these 18 mRNAs could also be found from the PCA dataset (n = 8 samples) listing the top 100 uEV mRNAs with low CV. This analysis showed 11 mRNAs in common (HSPD1, SRSF3, VAPA, RAB1A, MORF4L1, PGK1, RHOA, UBE2D3, DAZAP2, UBC, ACTG1) with low CV (Figure 4C, Table 6).




Figure 3. Urinary EV capture miRNAs associated with DKD. (**A,B,E**). Expression Heatmaps depict the expression of miRNAs associated with DKD and expressed in our uEV datasets. (**C,D**). Depict principal component analysis. (**A**). MiRNAs with evidence of dysregulation in kidney tissue and or cell lines and (**B,C**). miRNAs dysregulated in uEV/urine/urinary sediments. (**D**). MiRNAs with the highest fold changes from figure B which are part of the first and fourth cluster. The uEV expression data used in (**A–D**) corresponds to the UC isolation workflow dataset comprising healthy control and T1D macroalbuminuria groups ([13], part of our UC miRNA dataset in Tables 3 and 4). (**E**). The 31 miRNAs that could separate individuals with DKD and macroalbuminuria (as shown in B) were analyzed in the PCa uEV miRNA dataset [6]. Diabetic kidney disease (DKD), Prostate cancer (PCa), ultracentrifugation (UC), urinary extracellular vesicles (uEV).




Figure 4. Stable mRNA in common across diverse uEV datasets. Venn diagrams depict elements in common between the different datasets. (A–C). A 3-step search for the stable uEV mRNA using the top 100 genes with the lowest CV from each dataset. Diabetic kidney disease (DKD), prostate cancer (PCa), urinary extracellular vesicles (uEV).

We analyzed the counts per million (CPM) of the stable genes across samples. In addition, we included GAPDH, a commonly used reference gene, and a gene with high CV (UPK1A) for comparison (Table 6). CPM analysis showed that CPM variation of ACTG1 across samples was similar to the variation observed for GAPDH (both with high and comparable CPM, the rest of the stable mRNA had lower CPM than ACTG1 and GAPDH) but in both cases the variation was low compared to the gene with the highest CV (UPK1A) in all datasets (Figures 5, 6, S1 and S2). For visualization of CPM values across samples, the candidate reference genes were sorted by decreasing standard deviation (SD) value. The 5 genes with the lowest SD value are plotted in Figures 5 and 6A–D and the remaining 6 genes are plotted in Figures S1 and S2A,B. We also summarized the data in boxplots to visualize the CPM dispersion per gene (Figures 5E–H and 6C,D).

Table 5. miRNAs dysregulated in uEV/urine/urinary sediments from individuals with DKD. Cluster 1 and 4 (see Figure 3B) miRNAs and association with diabetic kidney disease or diabetic kidney disease associated mechanisms in kidney and/or other cells. Acute kidney injury (AKI), diabetic kidney disease (DKD), type 2 diabetes (T2D), urinary extracellular vesicle (uEV).

		Regulation in UC Dataset	Regulation in uEV/Urine/Urinary Sediments Literature	Examples of Association with Diabetic Kidney Disease or Kidney Diseases, or Pathways Associated with DKD (e.g., Fibrosis, Inflammation, Autophagy, and Oxidative Stress)
Cluster 1	miR-30b-5p	down	down	In hyperglycemic conditions, expression levels reduced in HK-2 cells and epithelial-mesenchymal transition was increased [99].
	miR-221-3p	down	down	In HUVEC cells, hyperglycemia induced this miRNA and was associated with impairment of endothelial cell migration and homing [157].
	miR-15b-5p	down	up	Upregulated in urine from db/db mouse and T2D patients. In mesangial cell lines hyperglycemia upregulates this miRNA and targets BCL-2 inducing apoptosis [72].
	let-7f-1-3p	down	down	Downregulated in plasma extracellular vesicles from patients with DKD [156].
	let-7a-3p	down	down	Downregulation after exposure to hypoxia in HT-29 cells [158].
Cluster 4	miR-424-5p	up	up	Upregulated in high fat diet fed mice and in hepatocytes treated with palmitate. MiR-424-5p suppressed insulin receptor expression in hepatocytes i.e., suggesting a role in insulin resistance [159].
	miR-486-3p	up	up	Downregulated in biopsies from patients with diabetic nephropathy [160].
	miR-335-5p	up	up	In mesangial cells, overexpression of miR-335 induces senescence and increases reactive oxygen species by targeting SOD2 [161].
	miR-126-3p	up	up	Increased in kidney biopsies from patients with DKD [91].

Table 6. Coefficient of variation (CV) of the stable genes across datasets. Diabetic kidney disease (DKD), prostate cancer (PCa), type 1 diabetes (T1D). * Commonly used reference gene for normalization of qPCR data. ** Gene with high CV in all datasets.

	CV					
	Isolation Workflows	DNase Treatment	Technical Datasets	DKD Cohort 1 (T1D, Men)	DKD Cohort 2 (T1D, Women)	PCa
HSPD1	0.23	0.13	0.15	0.14	0.16	0.12
SRSF3	0.21	0.13	0.17	0.15	0.18	0.16
VAPA	0.26	0.13	0.16	0.16	0.23	0.16
RAB1A	0.26	0.19	0.15	0.18	0.21	0.17
MORF4L1	0.22	0.13	0.17	0.21	0.16	0.16
PGK1	0.22	0.20	0.21	0.19	0.24	0.16
RHOA	0.17	0.16	0.19	0.15	0.22	0.16
UBE2D3	0.18	0.14	0.13	0.15	0.20	0.11

Table 6. Cont.

	CV					
	Isolation Workflows	DNase Treatment	Technical Datasets	DKD Cohort 1 (T1D, Men)	DKD Cohort 2 (T1D, Women)	PCa
DAZAP2	0.26	0.19	0.19	0.20	0.17	0.16
UBC	0.19	0.16	0.16	0.20	0.38	0.11
ACTG1	0.13	0.19	0.14	0.15	0.25	0.08
GAPDH *	0.18	0.20	0.17	0.19	0.24	0.29
UPK1A **	0.70	0.36	0.59	0.63	0.49	0.49

It has been suggested that a combination of reference genes could provide a more reliable and accurate normalization approach compared to individual reference genes. For generating such a normalization factor, it is important that genes are not co-regulated. In order to spot genes that may be co-regulated, we examined the functions and associated biological processes of the stable genes. As shown in Table 7, the reference gene’s functions (at the protein level) are varied including protein folding, glycolysis, signaling cascades, intracellular vesicular trafficking, and splicing. They also participate in several different prominent pathways. Of note, UBE and UBE2D3 both ubiquitylate proteins. Moreover, an analysis of protein interaction (based on experimental evidence from literature) using STRING showed interaction of UBC with UBE2D3 and DAZAP2 and of MORF4L1 with ACTG1 (Figure 7). In addition, RHOA is involved in some biological processes shared with other stable genes i.e., with RAB1A (cell migration and substrate adhesion-dependent cell spreading), ACTG1 (response to mechanical stimulus and regulation of focal adhesion assembly), DAZAP (positive regulation of protein serine/threonine kinase activity), and VAPA (positive regulation of I-kappaB kinase/NF-kappaB signaling) (Table 7).




Figure 5. Cont.




Figure 5. The mRNA sequencing read counts of candidate reference genes in pre-analytical and DKD uEV datasets from men. The uEV datasets included healthy controls and individuals with type 1 diabetes and different stages of albuminuria as well as comparisons of preanalytical variables (all male). (A–D). Line graphs depicts CPM of HSPD1, SRSF3, VAPA, RAB1A and MORF4L1 across samples and (E,F). Boxplots depict CPM per candidate reference genes. A reference gene used commonly for normalization (GAPDH) and a gene with high CV in all datasets (UPK1A) were included. (A,E). EV isolation workflows, (B,F). In column DNase treatment during uEV RNA extraction, (C,G). A technical dataset (type of urine collection, pre-clearing the urine before freezing, and technical replicates) and (D,H). DKD cohort 1. Sample pairs or triplicates are named similarly apart from the abbreviation of the tested variable. Centrifuged (C), Coefficient of variation (CV), counts per million (CPM), hydrostatic filtration dialysis (HFD), macroalbuminuria (Macro), microalbuminuria (Micro), normoalbuminuria (Normo), ultracentrifugation (UC).




Figure 6. Cont.




Figure 6. The mRNA sequencing read counts of the candidate reference genes in uEV datasets from DKD study of women and from prostate cancer patients. (A,B). Line graphs depicts CPM of HSPD1, SRSF3, VAPA, RAB1A and MORF4L1 across samples and (C,D). Boxplots depict CPM per candidate reference genes. A reference gene used commonly for normalization (GAPDH) and a gene with high CV in all datasets (UPK1A) were included. The uEV datasets included A. DKD cohort 2 (women with type 1 diabetes and different stages of albuminuria) and B. PCa patients and healthy controls (technical replicates, R1-3). Samples PCa1, 3 and 4 were obtained before prostatectomy. Sample PCa2 was obtained after prostatectomy from the same donor as PCa1. Coefficient of variation (CV), counts per million (CPM), macroalbuminuria (Macro), microalbuminuria (Micro), normoalbuminuria (Normo), prostate cancer (PCa).




Figure 7. Protein-protein interaction network analysis for the reference gene candidates. Network was generated using STRING (<https://string-db.org/>, accessed on 28 April 2023) and reproduced under Creative Commons BY 4.0 license (<https://creativecommons.org/licenses/by/4.0/>, accessed on 28 April 2023). Only interactions with experimental validation evidence in the literature are shown.

Table 7. Functions and gene ontology biological processes associated with the stable genes (GeneCards, www.genecards.org, accessed on 27 June 2023) and (Uniprot, <https://www.uniprot.org/>, accessed on 28 April 2023).

Gene Name	Entry	Protein Names	Function	Gene Ontology (Biological Process)
PGK1	P00558	Phosphoglycerate kinase 1	It catalyses the glycolytic pathway conversion of 1,3-diphosphoglycerate to 3-phosphoglycerate. It may act as a co-factor of polymerase alpha.	canonical glycolysis [GO:0061621]; cellular response to hypoxia [GO:0071456]; epithelial cell differentiation [GO:0030855]; gluconeogenesis [GO:0006094]; glycolytic process [GO:0006096]; negative regulation of angiogenesis [GO:0016525]; phosphorylation [GO:0016310]; plasminogen activation [GO:0031639]
UBC	P0CG48	Polyubiquitin-C	Polyubiquitin precursor. Ubiquitination has been associated with processes such as protein degradation, DNA repair, and cell cycle regulation.	modification-dependent protein catabolic process [GO:0019941]; protein ubiquitination [GO:0016567]
HSPD1	P10809	60 kDa heat shock protein, mitochondrial	Member of the chaperonin family. Essential role in folding and assembly of newly imported proteins in the mitochondria.	'de novo' protein folding [GO:0006458]; activation of cysteine-type endopeptidase activity involved in apoptotic process [GO:0006919]; apoptotic mitochondrial changes [GO:0008637]; B cell activation [GO:0042113]; B cell proliferation [GO:0042100]; biological process involved in interaction with symbiont [GO:0051702]; cellular response to interleukin-7 [GO:0098761]; chaperone-mediated protein complex assembly [GO:0051131]; isotype switching to IgG isotypes [GO:0048291]; mitochondrial unfolded protein response [GO:0034514]; MyD88-dependent toll-like receptor signaling pathway [GO:0002755]; negative regulation of apoptotic process [GO:0043066]; positive regulation of apoptotic process [GO:0043065]; positive regulation of interferon-alpha production [GO:0032727]; positive regulation of interleukin-10 production [GO:0032733]; positive regulation of interleukin-12 production [GO:0032735]; positive regulation of interleukin-6 production [GO:0032755]; positive regulation of macrophage activation [GO:0043032]; positive regulation of T cell activation [GO:0050870]; positive regulation of T cell mediated immune response to tumor cell [GO:0002842]; positive regulation of type II interferon production [GO:0032729]; protein folding [GO:0006457]; protein import into mitochondrial intermembrane space [GO:0045041]; protein maturation [GO:0051604]; protein refolding [GO:0042026]; protein stabilization [GO:0050821]; response to cold [GO:0009409]; response to unfolded protein [GO:0006986]; T cell activation [GO:0042110]

Table 7. Cont.

Gene Name	Entry	Protein Names	Function	Gene Ontology (Biological Process)
UBE2D3	P61077	Ubiquitin-conjugating enzyme E2 D3	Member of the E2 ubiquitin-conjugating enzyme family. This enzyme participates of the ubiquitination of proteins.	apoptotic process [GO:0006915]; DNA repair [GO:0006281]; negative regulation of BMP signaling pathway [GO:0030514]; negative regulation of transcription by RNA polymerase II [GO:0000122]; positive regulation of protein targeting to mitochondrion [GO:1903955]; proteasome-mediated ubiquitin-dependent protein catabolic process [GO:0043161]; protein autoubiquitination [GO:0051865]; protein K11-linked ubiquitination [GO:0070979]; protein K48-linked ubiquitination [GO:0070936]; protein modification process [GO:0036211]; protein monoubiquitination [GO:0006513]; protein polyubiquitination [GO:0000209]; protein ubiquitination [GO:0016567]
RHOA	P61586	Transforming protein RhoA	Member of the Rho family of small GTPases. These proteins function as molecular switches in signal transduction cascades.	actin cytoskeleton organization [GO:0030036]; actin cytoskeleton reorganization [GO:0031532]; actin filament organization [GO:0007015]; alpha-beta T cell lineage commitment [GO:0002363]; androgen receptor signaling pathway [GO:0030521]; angiotensin-mediated vasoconstriction involved in regulation of systemic arterial blood pressure [GO:0001998]; aortic valve formation [GO:0003189]; apical junction assembly [GO:0043297]; apolipoprotein A-I-mediated signaling pathway [GO:0038027]; beta selection [GO:0043366]; cell junction assembly [GO:0034329]; cell migration [GO:0016477]; cell-matrix adhesion [GO:0007160]; cellular response to chemokine [GO:1990869]; cellular response to cytokine stimulus [GO:0071345]; cellular response to lipopolysaccharide [GO:0071222]; cerebral cortex cell migration [GO:0021795]; cleavage furrow formation [GO:0036089]; cortical cytoskeleton organization [GO:0030865]; cytoplasmic microtubule organization [GO:0031122]; endothelial cell migration [GO:0043542]; endothelial tube lumen extension [GO:0097498]; establishment of epithelial cell apical/basal polarity [GO:0045198]; establishment or maintenance of cell polarity [GO:0007163]; forebrain radial glial cell differentiation [GO:0021861]; GTP metabolic process [GO:0046039]; kidney development [GO:0001822]; mitotic cleavage furrow formation [GO:1903673]; mitotic spindle assembly [GO:0090307]; motor neuron apoptotic process [GO:0097049]; negative chemotaxis [GO:0050919]; negative regulation of cell migration involved in

Table 7. Cont.

Gene Name	Entry	Protein Names	Function	Gene Ontology (Biological Process)
RHOA	P61586	Transforming protein RhoA	Member of the Rho family of small GTPases. These proteins function as molecular switches in signal transduction cascades.	sprouting angiogenesis [GO:0090051]; negative regulation of cell size [GO:0045792]; negative regulation of cell-substrate adhesion [GO:0010812]; negative regulation of I-kappaB kinase/NF-kappaB signaling [GO:0043124]; negative regulation of intracellular steroid hormone receptor signaling pathway [GO:0033144]; negative regulation of motor neuron apoptotic process [GO:2000672]; negative regulation of neuron differentiation [GO:0045665]; negative regulation of neuron projection development [GO:0010977]; negative regulation of oxidative phosphorylation [GO:0090324]; negative regulation of reactive oxygen species biosynthetic process [GO:1903427]; negative regulation of vascular associated smooth muscle cell migration [GO:1904753]; negative regulation of vascular associated smooth muscle cell proliferation [GO:1904706]; neuron migration [GO:0001764]; neuron projection morphogenesis [GO:0048812]; odontogenesis [GO:0042476]; ossification involved in bone maturation [GO:0043931]; positive regulation of actin filament polymerization [GO:0030838]; positive regulation of alpha-beta T cell differentiation [GO:0046638]; positive regulation of cell growth [GO:0030307]; positive regulation of cysteine-type endopeptidase activity involved in apoptotic process [GO:0043280]; positive regulation of cytokinesis [GO:0032467]; positive regulation of I-kappaB kinase/NF-kappaB signaling [GO:0043123]; positive regulation of leukocyte adhesion to vascular endothelial cell [GO:1904996]; positive regulation of lipase activity [GO:0060193]; positive regulation of neuron apoptotic process [GO:0043525]; positive regulation of neuron differentiation [GO:0045666]; positive regulation of NIK/NF-kappaB signaling [GO:1901224]; positive regulation of podosome assembly [GO:0071803]; positive regulation of protein serine/threonine kinase activity [GO:0071902]; positive regulation of stress fiber assembly [GO:0051496]; positive regulation of T cell migration [GO:2000406]; positive regulation of translation [GO:0045727]; positive regulation of vascular associated smooth muscle contraction [GO:1904695]; regulation of actin cytoskeleton organization [GO:0032956]; regulation of calcium ion transport [GO:0051924]; regulation of cell migration [GO:0030334]; regulation of cell shape [GO:0008360]; regulation of dendrite development [GO:0050773]; regulation of focal adhesion assembly [GO:0051893]; regulation of microtubule cytoskeleton organization [GO:0070507]; regulation of modification of

Table 7. Cont.

Gene Name	Entry	Protein Names	Function	Gene Ontology (Biological Process)
RHOA	P61586	Transforming protein RhoA	Member of the Rho family of small GTPases. These proteins function as molecular switches in signal transduction cascades.	postsynaptic actin cytoskeleton [GO:1905274]; regulation of modification of postsynaptic structure [GO:0099159]; regulation of neural precursor cell proliferation [GO:2000177]; regulation of osteoblast proliferation [GO:0033688]; regulation of systemic arterial blood pressure by endothelin [GO:0003100]; regulation of transcription by RNA polymerase II [GO:0006357]; response to amino acid [GO:0043200]; response to ethanol [GO:0045471]; response to glucocorticoid [GO:0051384]; response to glucose [GO:0009749]; response to hypoxia [GO:0001666]; response to mechanical stimulus [GO:0009612]; response to xenobiotic stimulus [GO:0009410]; Rho protein signal transduction [GO:0007266]; Roundabout signaling pathway [GO:0035385]; skeletal muscle satellite cell migration [GO:1902766]; skeletal muscle tissue development [GO:0007519]; stress fiber assembly [GO:0043149]; stress-activated protein kinase signaling cascade [GO:0031098]; substantia nigra development [GO:0021762]; substrate adhesion-dependent cell spreading [GO:0034446]; trabecula morphogenesis [GO:0061383]; Wnt signaling pathway, planar cell polarity pathway [GO:0060071]; wound healing, spreading of cells [GO:0044319]
RAB1A	P62820	Ras-related protein Rab-1A	Member of the Ras superfamily of GTPases. These proteins act as regulators of intracellular membrane trafficking.	autophagosome assembly [GO:0000045]; autophagy [GO:0006914]; cell migration [GO:0016477]; COPII-coated vesicle cargo loading [GO:0090110]; defense response to bacterium [GO:0042742]; endocytosis [GO:0006897]; endoplasmic reticulum to Golgi vesicle-mediated transport [GO:0006888]; Golgi organization [GO:0007030]; growth hormone secretion [GO:0030252]; intracellular protein transport [GO:0006886]; melanosome transport [GO:0032402]; positive regulation of glycoprotein metabolic process [GO:1903020]; positive regulation of interleukin-8 production [GO:0032757]; substrate adhesion-dependent cell spreading [GO:0034446]; vesicle transport along microtubule [GO:0047496]; vesicle-mediated transport [GO:0016192]; virion assembly [GO:0019068]

Table 7. Cont.

Gene Name	Entry	Protein Names	Function	Gene Ontology (Biological Process)
ACTG1	P63261	Actin, cytoplasmic 2	Cytoplasmic actin expressed in all cell types.	angiogenesis [GO:0001525]; cellular response to type II interferon [GO:0071346]; maintenance of blood-brain barrier [GO:0035633]; morphogenesis of a polarized epithelium [GO:0001738]; platelet aggregation [GO:0070527]; positive regulation of cell migration [GO:0030335]; positive regulation of gene expression [GO:0010628]; positive regulation of wound healing [GO:0090303]; protein localization to bicellular tight junction [GO:1902396]; regulation of focal adhesion assembly [GO:0051893]; regulation of stress fiber assembly [GO:0051492]; regulation of synaptic vesicle endocytosis [GO:1900242]; regulation of transepithelial transport [GO:0150111]; response to calcium ion [GO:0051592]; response to mechanical stimulus [GO:0009612]; retina homeostasis [GO:0001895]; sarcomere organization [GO:0045214]; tight junction assembly [GO:0120192]
SRSF3	P84103	Serine/arginine-rich splicing factor 3 (Pre-mRNA-splicing factor SRP20)	Member of the serine/arginine (SR)-rich family of pre-mRNA splicing factors. This protein is part of the spliceosome.	cellular response to leukemia inhibitory factor [GO:1990830]; mRNA export from nucleus [GO:0006406]; mRNA splicing, via spliceosome [GO:0000398]; primary miRNA processing [GO:0031053]; regulation of mRNA splicing, via spliceosome [GO:0048024]
DAZAP2	Q15038	DAZ-associated protein 2 (Deleted in azoospermia-associated protein 2)	Proline rich protein that is involved in various biological processes by interacting with proteins such as DAZ and function.	positive regulation of protein serine/threonine kinase activity [GO:0071902]; positive regulation of RNA polymerase II regulatory region sequence-specific DNA binding [GO:1905636]; protein destabilization [GO:0031648]; stress granule assembly [GO:0034063]
VAPA	Q9P0L0	Vesicle-associated membrane protein-associated protein A (VAMP-A)	Transmembrane protein which may involve function in vesicle trafficking, membrane fusion, protein complex assembly and cell motility.	cell death [GO:0008219]; ceramide transport [GO:0035627]; COPII-coated vesicle budding [GO:0090114]; endoplasmic reticulum to Golgi vesicle-mediated transport [GO:0006888]; membrane fusion [GO:0061025]; negative regulation by host of viral genome replication [GO:0044828]; neuron projection development [GO:0031175]; phospholipid transport [GO:0015914]; positive regulation by host of viral genome replication [GO:0044829]; positive regulation of I-kappaB kinase/NF-kappaB signaling [GO:0043123]; protein localization to endoplasmic reticulum [GO:0070972]; sphingomyelin biosynthetic process [GO:0006686]; sterol transport [GO:0015918]; viral release from host cell [GO:0019076]

Table 7. Cont.

Gene Name	Entry	Protein Names	Function	Gene Ontology (Biological Process)
MORF4L1	Q9UBU8	Mortality factor 4-like protein 1 (MORF-related gene 15 protein)	Involved in transcriptional activation by being part of the NuA4 histone acetyltransferase (HAT) complex.	chromatin organization [GO:0006325]; double-strand break repair via homologous recombination [GO:0000724]; fibroblast proliferation [GO:0048144]; histone acetylation [GO:0016573]; histone deacetylation [GO:0016575]; histone H2A acetylation [GO:0043968]; histone H4 acetylation [GO:0043967]; positive regulation of DNA-templated transcription [GO:0045893]; positive regulation of double-strand break repair via homologous recombination [GO:1905168]; regulation of apoptotic process [GO:0042981]; regulation of cell cycle [GO:0051726]; regulation of double-strand break repair [GO:2000779]

Further we analyzed the stability of the candidate reference genes in datasets from samples that did not perform well in mRNA sequencing i.e., urines stored at -20°C and uEV isolated with NG isolation workflow. We found that all genes were less stable in samples stored at -20°C and in NG isolates (Figure S3). Of note, in many NG samples the candidate reference genes were not detected. Despite of this, HSPD1, SRSF3, VAPA, RAB1A, MORF4L1, PGK1, RHOA, UBE2D3, DAZAP2, UBC, ACTG1, showed to be stable in all other diverse experimental conditions and across disease groups. Thus, they may serve as reference genes for uEV mRNA related research.

4. Discussion

Urinary EV have been regarded as a promising source of biomarkers [5] and this idea is getting support from an increasing number of studies reporting candidate markers for diseases of diverse etiology [8,9,28,162,163]. However, many obstacles prevent replication of biomarker results and, as a consequence, clinical translation. In this study, we approached three of these obstacles: urine storage, uEV isolation and reference genes in kidney disease transcriptomic research.

The first obstacle is the lack of guidelines to handle and store urine. Urine storage temperature (-20°C vs. -80°C) has been shown to affect the size and concentration of uEV [164] and recovery of uEV protein markers but the latter could be sorted out by vortexing samples after thawing [165]. In addition, qPCR-based research has been done on uEV RNA by comparing storage temperatures—including -80°C , 4°C , room temperature and 37°C with variable results [166–168]. Our group showed that the global uEV miRNA and mRNA profiles were affected when urines were stored at -20°C vs. -80°C [14] and we found sets of downregulated and upregulated genes. As particularly the -20°C downregulated genes were involved e.g., in carbohydrate or lipid metabolism, the result suggested that -20°C stored samples are less useful for studying kidney diseases. Here, analyzing further the data, we found that a striking 75% of the -20°C downregulated miRNAs were associated with various kidney diseases (Table 2). Thus, the result reinforces the idea of avoiding urine samples stored at suboptimal temperatures [14], because such samples might not contain putative valuable disease markers anymore.

We also observed that despite the normalized differential expression, miRNAs that were up-regulated in samples stored at -20°C had still lower raw counts than the same miRNAs in -80°C stored samples. Thus, the result was the opposite than what the normalized counts showed. TMM normalization is a method based on library size that uses scaling of raw reads to render library sizes comparable which is needed for differential expression analysis [169]. Considering that the library size of the -20°C samples was smaller (higher number of 0 raw counts and lower expression in general) than that of the -80°C samples, the upregulation of miRNAs in -20°C samples may be an artifact of the data analysis. Further, we showed that kidney-RNAs were detected in small quantities after storage at -20°C (Figure 1). In particular, kidney enriched mRNAs in uEV isolates were highly affected since almost one third (30%) of them were not detected at all in samples stored at -20°C . Our results agree with and provide further support to a set of urine storage guidelines that has been published recently [17].

The second obstacle is the lack of standardization of uEV isolation methods. Currently, many isolation principles and workflows are available [170] and it is well known that they typically produce different results [13,15,16,168,171]. Obviously, this represents a problem for study comparisons, even if reporting guidelines now help to identify differences, facilitate replication and/or explain the lack of it [12,172]. Prior studies have explored the effect of uEV isolation workflows on uEV RNA sequencing profiles focusing on miRNA sequencing [15,20–22]. We have previously demonstrated that the uEV isolation workflow (UC, HFD and NG) has a surprisingly variable impact on the miRNA and mRNA profiles [13]. Specifically, global miRNA profile analysis suggested that the three workflows were similar overall or—at least—did not differ systematically. This was in contrast to the global mRNA results, where UC and HFD were similar while NG clustered

separately [13]. Here, by analyzing the top expressed miRNAs of the kidney, we found that the expression of 18 miRNAs was lower for a set of HFD samples compared to UC and NG samples (Figure 2). While for 13 miRNAs the differences in the expression levels between UC and HFD were small (3–35%) and could be related to technical bias, for 5 miRNAs differences were in the range of 35–55% and could represent real differences. Of note, miRNA hsa-miR-101-3p (a top kidney expressed miRNA) was significantly downregulated in HFD relative to UC samples [13]. The observation that methods capture slightly different kidney enriched miRNAs could be explained, at least partly, by differences in the uEV populations and/or non-EV components captured by the isolation workflows [13]. On the other hand, analysis of kidney enriched mRNAs was consistent with the global analysis i.e., NG samples could not capture these genes as well as UC and HFD (Figure 2). Thus, this shows that for a specific research topic like kidney research, it is best to evaluate the differences between methods using specific end-point targets (kidney-RNAs) in addition to a global level analysis.

In addition to urine storage temperature and uEV isolation workflows, many other preanalytical experimental conditions impact the analytical endpoints as well [12]. As experimental set-ups can differ greatly between studies [18], biomarker results cannot be replicated hindering translation of findings to clinic [173]. Considering all the variability, we were positively surprised that our UC workflow replicated some of the previous results from DKD miRNA studies using uEV or urine/urine sediments (see Table 4) i.e., a set of the miRNAs separated experimental groups (healthy controls vs. T1D with macroalbuminuria) (Figure 3). Further, specifically eight miRNAs followed the same regulation direction in both the literature and our dataset. Three of the eight miRNAs had also evidence of DKD-linked dysregulation in kidney or plasma of individuals with DKD and two showed to be dysregulated in kidney cell lines under hyperglycemic conditions in vitro (in addition to evidence in urine/uEV) and all of them related to pathological mechanisms in DKD such as fibrosis and impaired autophagy [174–176] (Table 5). However, our dataset had a low number of samples and thus replication of findings in bigger and more varied cohorts is still needed. Interestingly, we found 12 miRNAs in common between the two literature review generated DKD miRNA lists. These miRNAs were associated with pathological pathways involved in DKD such as hypertrophy and fibrosis. These results suggest that the uEV capture a specific subset of DKD-associated miRNA reflecting the differences in the tissue.

The third obstacle jeopardizing the biomarker replication is the lack of normalizers—in the EV transcriptomics field, this means lack of stable reference genes across e.g., many preanalytical workflows and disease conditions. Urinary EV reference genes are a poorly explored topic. While some recommendations exist on how to select reference genes or normalize gene expression data [29,30,177], there are only few studies on this topic in urine. GAPDH, a commonly used reference gene, and UBC were the most stable in EV derived from liver and breast cancer cell lines [33]. In contrast, Singh et al. (2022) tested five common reference genes (including GAPDH) and found that B2M and RPL13 were the most stable in uEV isolated using PEG from patients with renal graft dysfunction. Thus, the stability of GAPDH appears to be dependent on the disease, biofluid and/or EV isolation method. In this study, using datasets available in our original publications [6,9,13,14], we discovered 11 mRNAs (HSPD1, SRSF3, VAPA, RAB1A, MORF4L1, PGK1, RHOA, UBE2D3, DAZAP2, UBC, ACTG1) that were stable across datasets including different pre-analytical conditions, men and women, healthy controls, T1D and T2D patients with different albuminuria status; and prostate cancer patients (Figures 4–6, S1 and S2). However, in poor quality sequencing datasets (urine stored at -20°C and NG isolation workflow), the candidate genes showed poor stability i.e., high CV (Figure S3). Of note, our finding regarding UBC stability in uEV is concordant with findings of Gorgi Bahri (2021) in cell culture media derived EV. Further, even though GAPDH was not one of the most stable mRNAs, it was less variable than UPK1A (a highly variable mRNA selected to compare our candidate reference mRNAs).

One of the reasons that prevents the study of uEV reference genes is the lack of data. Many studies have focused on miRNA/small RNA sequencing, but only few on RNA sequencing. Moreover, the few studies with a good amount of uEV samples from patients [59,178] do not have the associated raw sequencing data and/or raw sequencing counts freely available (to date). Local regulations could hinder the publication of sequencing data but raw count data describing all the pre-processing and alignment procedures is also helpful for the research community. Such practicalities should be considered for the informed consent and ethical permissions. Given more available datasets in future, the stability of our 11 candidate mRNAs could be further tested and a combination of selected genes used as reference genes e.g., by calculating the geometrical mean [179]. As it is recommended that reference genes should belong to different biological pathways and that expression is regulated independently for each reference gene, caution should be taken if using UBC and UBED3 and/or DAZAP2 or MORF4L1 and ACTG1 together since an analysis using STRING showed evidence of experimentally validated interactions in the literature (Figure 7). In addition, UBC and UBE2D3 are co-expressed (<https://string-db.org/>, accessed on 28 April 2023) and form a protein complex [180]. Moreover, RHOA shared biological processes with RAB1A, ACTG1, DAZAP and VAPA (Table 7). It is good to keep in mind that the uEV reference mRNA candidates could be contributing to biological processes associated with kidney diseases e.g., RAB1A contributes to autophagy. Nevertheless, their stability in our datasets which included isolates from healthy and type 1 diabetic individuals with and without DKD, and diverse preanalytical setups (roughly 200 isolates) motivates further experimental validations.

We acknowledge that a full understanding of the effect of all pre-analytical choices and pathophysiological conditions for transcriptomic applications calls for big testing resources. Ideally, cross-laboratory testing should be performed, and laboratories could implement reference materials, a gold standard isolation protocol, and housekeeping normalizers. Our results here help towards this goal by providing new insights for the three key obstacles hindering uEV biomarker validation. For the first two, urine storage and uEV isolation, we found that it is important to study the raw counts in addition to the normalized counts and kidney-RNAs in addition to the global transcriptome—they offer different although complementary results. For the third, the reference genes, we provide 11 mRNAs that could be tested for qPCR normalization in the context of DKD and prostate cancer. Finally, despite the known and hereby addressed variability between uEV studies, we successfully replicated many previously found urine/uEV/urinary pellet miRNAs associated with DKD in our UC DKD dataset. We regard this as an encouraging result for the reproducibility of uEV biomarker research.

Supplementary Materials: The following supporting information can be downloaded at: <https://www.mdpi.com/article/10.3390/genes14071415/s1>, Figure S1: The mRNA sequencing read counts of six of the eleven candidate reference genes across samples in pre-analytical and DKD uEV datasets from men. Figure S2: The mRNA sequencing read counts of six of the eleven candidate reference genes across samples in uEV datasets from DKD study of women and from prostate cancer patients. Figure S3: The mRNA sequencing read counts of candidate reference genes in storage temperature and NG datasets. Table S1: Dysregulated miRNAs in samples stored at -20°C , raw and normalized counts. Table S2: Kidney-RNAs raw and normalized counts for storage temperature dataset. Table S3: Kidney-RNAs raw and normalized counts for Isolation workflows.

Author Contributions: Made substantial contributions to conceptualization: K.B. and M.P.; investigation: K.B., O.P.D., A.R., H.H., T.T., P.-H.G. and M.P.; formal analysis and visualization: K.B. and M.P.; supervision: M.P.; writing-original draft: K.B. and M.P.; writing-review and editing: all authors contributed. All authors have read and agreed to the published version of the manuscript.

Funding: This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 115974. The JU receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA and JDRF. Any dissemination of results reflects only the author's view; the JU is not responsible for any use that may be made of the information it contains. Open access funding provided by University of Helsinki.

Institutional Review Board Statement: The original studies, where the datasets were generated, were conducted in accordance with the Declaration of Helsinki, and approved by the pertinent Institutional Review Board as reported in [6,9,13,14].

Informed Consent Statement: Informed consent was obtained from all subjects involved in the study as reported in [6,9,13,14].

Data Availability Statement: Datasets used in this publication are available in the original publications mentioned in Table 1.

Acknowledgments: We acknowledge the ISEV Urine Task force and BEAt-DKD project partners for discussions and inspiration.

Conflicts of Interest: K.B., O.D.P., H.H., T.T. and M.P. declare no conflict of interest. P-H.G. has received research grants from Eli Lilly and Roche; is an advisory board member for AbbVie, AstraZeneca, Boehringer Ingelheim, Cebix, Eli Lilly, Jansen, MSD, Novartis, NovoNordisk and Sanofi; and has received lecture fees from Boehringer Ingelheim, Eli Lilly, Elo Water, Genzyme, MSD, Novartis, Novo Nordisk and Sanofi. K.B., O.D.P., H.H., T.T. and M.P. declare no conflict of interest.

References

1. De Freitas, R.C.C.; Hirata, R.D.C.; Hirata, M.H.; Aikawa, E. Circulating Extracellular Vesicles As Biomarkers and Drug Delivery Vehicles in Cardiovascular Diseases. *Biomolecules* **2021**, *11*, 388. [CrossRef] [PubMed]
2. Xu, K.; Liu, Q.; Wu, K.; Liu, L.; Zhao, M.; Yang, H.; Wang, X.; Wang, W. Extracellular vesicles as potential biomarkers and therapeutic approaches in autoimmune diseases. *J. Transl. Med.* **2020**, *18*, 432. [CrossRef] [PubMed]
3. Rodosthenous, R.S.; Hutchins, E.; Reiman, R.; Yeri, A.S.; Srinivasan, S.; Whittsett, T.G.; Ghiran, I.; Silverman, M.G.; Laurent, L.C.; Van Keuren-Jensen, K.; et al. Profiling Extracellular Long RNA Transcriptome in Human Plasma and Extracellular Vesicles for Biomarker Discovery. *iScience* **2020**, *23*, 101182. [CrossRef] [PubMed]
4. Svenningsen, P.; Sabaratnam, R.; Jensen, B.L. Urinary extracellular vesicles: Origin, role as intercellular messengers and biomarkers; efficient sorting and potential treatment options. *Acta Physiol.* **2020**, *228*, e13346. [CrossRef]
5. Erdbrügger, U.; Le, T.H. Extracellular Vesicles in Renal Diseases: More than Novel Biomarkers? *J. Am. Soc. Nephrol.* **2016**, *27*, 12–26. [CrossRef]
6. Puhka, M.; Thierens, L.; Nicorici, D.; Forsman, T.; Mirtti, T.; Hällström, T.A.; Serkkola, E.; Rannikko, A. Exploration of Extracellular Vesicle miRNAs, Targeted mRNAs and Pathways in Prostate Cancer: Relation to Disease Status and Progression. *Cancers* **2022**, *14*, 532. [CrossRef]
7. Miranda, K.C.; Bond, D.T.; McKee, M.; Skog, J.; Păunescu, T.G.; Da Silva, N.; Brown, D.; Russo, L.M. Nucleic acids within urinary exosomes/microvesicles are potential biomarkers for renal disease. *Kidney Int.* **2010**, *78*, 191–199. [CrossRef]
8. Margolis, E.; Brown, G.; Partin, A.; Carter, B.; McKiernan, J.; Tutrone, R.; Torkler, P.; Fischer, C.; Tadigotla, V.; Noerholm, M.; et al. Predicting high-grade prostate cancer at initial biopsy: Clinical performance of the ExoDx (EPI) Prostate Intelliscore test in three independent prospective studies. *Prostate Cancer Prostatic Dis.* **2022**, *25*, 296–301. [CrossRef]
9. Dwivedi, O.P.; Barreiro, K.; Käräjämäki, A.; Valo, E.; Giri, A.K.; Prasad, R.B.; Das Roy, R.; Thorn, L.M.; Rannikko, A.; Holthöfer, H.; et al. Genome-wide mRNA profiling in urinary extracellular vesicles reveals stress gene signature for diabetic kidney disease. *iScience* **2023**, *26*, 106686. [CrossRef]
10. Zubiri, I.; Posada-Ayala, M.; Sanz-Maroto, A.; Calvo, E.; Martin-Lorenzo, M.; Gonzalez-Calero, L.; de la Cuesta, F.; Lopez, J.A.; Fernandez-Fernandez, B.; Ortiz, A.; et al. Diabetic nephropathy induces changes in the proteome of human urinary exosomes as revealed by label-free comparative analysis. *J. Proteom.* **2014**, *96*, 92–102. [CrossRef]
11. Chen, Y.-H.; Chen, Z.-W.; Li, H.-M.; Yan, X.-F.; Feng, B. AGE/RAGE-Induced EMP Release via the NOX-Derived ROS Pathway. *J. Diabetes Res.* **2018**, *2018*, 6823058. [CrossRef]
12. Erdbrügger, U.; Blijdorp, C.J.; Bijnsdorp, I.V.; Borràs, F.E.; Burger, D.; Bussolati, B.; Byrd, J.B.; Clayton, A.; Dear, J.W.; Falcón-Pérez, J.M.; et al. Urinary extracellular vesicles: A position paper by the Urine Task Force of the International Society for Extracellular Vesicles. *J. Extracell. Vesicles* **2021**, *10*, e12093. [CrossRef]
13. Barreiro, K.; Dwivedi, O.P.; Leparç, G.; Rolser, M.; Delic, D.; Forsblom, C.; Groop, P.; Groop, L.; Huber, T.B.; Puhka, M.; et al. Comparison of urinary extracellular vesicle isolation methods for transcriptomic biomarker research in diabetic kidney disease. *J. Extracell. Vesicles* **2020**, *10*, e12038. [CrossRef]

14. Barreiro, K.; Dwivedi, O.P.; Valkonen, S.; Groop, P.; Tuomi, T.; Holthofer, H.; Rannikko, A.; Yliperttula, M.; Siljander, P.; Laitinen, S.; et al. Urinary extracellular vesicles: Assessment of pre-analytical variables and development of a quality control with focus on transcriptomic biomarker research. *J. Extracell. Vesicles* **2021**, *10*, e12158. [[CrossRef](#)]
15. Mussack, V.; Wittmann, G.; Pfaffl, M.W. Comparing small urinary extracellular vesicle purification methods with a view to RNA sequencing—Enabling robust and non-invasive biomarker research. *Biomol. Detect. Quantif.* **2019**, *17*, 100089. [[CrossRef](#)]
16. Dong, L.; Zieren, R.C.; Horie, K.; Kim, C.; Mallick, E.; Jing, Y.; Feng, M.; Kuczler, M.D.; Green, J.; Amend, S.R.; et al. Comprehensive evaluation of methods for small extracellular vesicles separation from human plasma, urine and cell culture medium. *J. Extracell. Vesicles* **2020**, *10*, e12044. [[CrossRef](#)]
17. van Royen, M.E.; Soekmadji, C.; Grange, C.; Webber, J.P.; Tertel, T.; Droste, M.; Buescher, A.; Giebel, B.; Jenster, G.W.; Llorente, A.; et al. The quick reference card “Storage of urinary EVs”—A practical guideline tool for research and clinical laboratories. *J. Extracell. Vesicles* **2023**, *12*, e12286. [[CrossRef](#)]
18. López-Guerrero, J.A.; Valés-Gómez, M.; Borrás, F.E.; Falcón-Pérez, J.M.; Vicent, M.J.; Yáñez-Mó, M. Standardising the pre-analytical reporting of biospecimens to improve reproducibility in extracellular vesicle research—A GEIVEX study. *J. Extracell. Biol.* **2023**, *2*, e76. [[CrossRef](#)]
19. Nieuwland, R.; Siljander, P.R.-M.; Falcón-Pérez, J.M.; Witwer, K.W. Reproducibility of extracellular vesicle research. *Eur. J. Cell Biol.* **2022**, *101*, 151226. [[CrossRef](#)]
20. García-Flores, M.; Sánchez-López, C.M.; Ramírez-Calvo, M.; Fernández-Serra, A.; Marcilla, A.; López-Guerrero, J.A. Isolation and characterization of urine microvesicles from prostate cancer patients: Different approaches, different visions. *BMC Urol.* **2021**, *21*, 137. [[CrossRef](#)]
21. Park, S.; Lee, K.; Park, I.B.; Kim, N.H.; Cho, S.; Rhee, W.J.; Oh, Y.; Choi, J.; Nam, S.; Lee, D.H. The profiles of microRNAs from urinary extracellular vesicles (EVs) prepared by various isolation methods and their correlation with serum EV microRNAs. *Diabetes Res. Clin. Pract.* **2020**, *160*, 108010. [[CrossRef](#)] [[PubMed](#)]
22. Srinivasan, S.; Yeri, A.; Cheah, P.S.; Chung, A.; Danielson, K.; De Hoff, P.; Filant, J.; Laurent, C.D.; Laurent, L.D.; Magee, R.; et al. Small RNA Sequencing across Diverse Biofluids Identifies Optimal Methods for exRNA Isolation. *Cell* **2019**, *177*, 446–462. e16. [[CrossRef](#)]
23. Miranda, K.C.; Bond, D.T.; Levin, J.; Adiconis, X.; Sivachenko, A.; Russ, C.; Brown, D.; Nusbaum, C.; Russo, L.M. Massively Parallel Sequencing of Human Urinary Exosome/Microvesicle RNA Reveals a Predominance of Non-Coding RNA. *PLoS ONE* **2014**, *9*, e96094. [[CrossRef](#)] [[PubMed](#)]
24. Blijdorp, C.J.; Hartjes, T.A.; Wei, K.; van Heugten, M.H.; Bovée, D.M.; Budde, R.P.; van de Wetering, J.; Hoenderop, J.G.; van Royen, M.E.; Zietse, R.; et al. Nephron mass determines the excretion rate of urinary extracellular vesicles. *J. Extracell. Vesicles* **2022**, *11*, e12181. [[CrossRef](#)] [[PubMed](#)]
25. Bazzell, B.G.; Rainey, W.E.; Auchus, R.J.; Zocco, D.; Bruttini, M.; Hummel, S.L.; Byrd, J.B. Human Urinary mRNA as a Biomarker of Cardiovascular Disease. *Circ. Genom. Precis. Med.* **2018**, *11*, e002213. [[CrossRef](#)]
26. Zhang, W.; Zhou, X.; Zhang, H.; Yao, Q.; Liu, Y.; Dong, Z.; Fenton, R.A.; Asvapromtada, S.; Sonoda, H.; Kinouchi, M.; et al. Extracellular vesicles in diagnosis and therapy of kidney diseases. *Am. J. Physiol. Physiol.* **2016**, *311*, F844–F851. [[CrossRef](#)]
27. Jia, Y.; Guan, M.; Zheng, Z.; Zhang, Q.; Tang, C.; Xu, W.; Xiao, Z.; Wang, L.; Xue, Y. miRNAs in Urine Extracellular Vesicles as Predictors of Early-Stage Diabetic Nephropathy. *J. Diabetes Res.* **2016**, *2016*, 7932765. [[CrossRef](#)]
28. Zang, J.; Maxwell, A.P.; Simpson, D.A.; McKay, G.J. Differential Expression of Urinary Exosomal MicroRNAs miR-21-5p and miR-30b-5p in Individuals with Diabetic Kidney Disease. *Sci. Rep.* **2019**, *9*, 10900. [[CrossRef](#)]
29. Dai, Y.; Cao, Y.; Köhler, J.; Lu, A.; Xu, S.; Wang, H. Unbiased RNA-Seq-driven identification and validation of reference genes for quantitative RT-PCR analyses of pooled cancer exosomes. *BMC Genom.* **2021**, *22*, 27. [[CrossRef](#)]
30. Gouin, K.; Peck, K.; Antes, T.; Johnson, J.L.; Li, C.; Vaturi, S.D.; Middleton, R.; de Couto, G.; Walravens, A.S.; Rodriguez-Borlado, L.; et al. A comprehensive method for identification of suitable reference genes in extracellular vesicles. *J. Extracell. Vesicles* **2017**, *6*, 1347019. [[CrossRef](#)]
31. Kozera, B.; Rapacz, M. Reference genes in real-time PCR. *J. Appl. Genet.* **2013**, *54*, 391–406. [[CrossRef](#)]
32. Singh, A.D.; Patnam, S.; Koyyada, R.; Samal, R.; Alvi, S.B.; Satyanaryana, G.; Andrews, R.; Panigrahi, A.K.; Rengan, A.K.; Mudigonda, S.S.; et al. Identifying stable reference genes in polyethylene glycol precipitated urinary extracellular vesicles for RT-qPCR-based gene expression studies in renal graft dysfunction patients. *Transpl. Immunol.* **2022**, *75*, 101715. [[CrossRef](#)]
33. Gorji-Bahri, G.; Moradtabrizi, N.; Vakhshiteh, F.; Hashemi, A. Validation of common reference genes stability in exosomal mRNA-isolated from liver and breast cancer cell lines. *Cell Biol. Int.* **2021**, *45*, 1098–1110. [[CrossRef](#)]
34. Habuka, M.; Fagerberg, L.; Hallström, B.M.; Kampf, C.; Edlund, K.; Sivertsson, Å.; Yamamoto, T.; Pontén, F.; Uhlén, M.; Odeberg, J. The Kidney Transcriptome and Proteome Defined by Transcriptomics and Antibody-Based Profiling. *PLoS ONE* **2014**, *9*, e116125. [[CrossRef](#)]
35. Uhlén, M.; Fagerberg, L.; Hallström, B.M.; Lindskog, C.; Oksvold, P.; Mardinoglu, A.; Sivertsson, Å.; Kampf, C.; Sjöstedt, E.; Asplund, A.; et al. Proteomics. Tissue-Based Map of the Human Proteome. *Science* **2015**, *347*, 1260419. [[CrossRef](#)]
36. Keller, A.; Gröger, L.; Tschernig, T.; Solomon, J.; Laham, O.; Schaum, N.; Wagner, V.; Kern, F.; Schmartz, G.P.; Li, Y.; et al. miRNATissueAtlas2: An update to the human miRNA tissue atlas. *Nucleic Acids Res.* **2022**, *50*, D211–D221. [[CrossRef](#)]
37. Robinson, M.D.; Oshlack, A. A scaling normalization method for differential expression analysis of RNA-seq data. *Genome Biol.* **2010**, *11*, R25. [[CrossRef](#)]

38. Robinson, M.D.; McCarthy, D.J.; Smyth, G.K. EdgeR: A Bioconductor package for differential expression analysis of digital gene expression data. *Bioinformatics* **2010**, *26*, 139–140. [[CrossRef](#)]
39. Anders, S.; Huber, W. Differential expression analysis for sequence count data. *Genome Biol.* **2010**, *11*, R106. [[CrossRef](#)]
40. Love, M.I.; Huber, W.; Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. *Genome Biol.* **2014**, *15*, 550. [[CrossRef](#)]
41. Stelzer, G.; Rosen, N.; Plaschkes, I.; Zimmerman, S.; Twik, M.; Fishilevich, S.; Stein, T.I.; Nudel, R.; Lieder, I.; Mazor, Y.; et al. The GeneCards Suite: From Gene Data Mining to Disease Genome Sequence Analyses. *Curr. Protoc. Bioinform.* **2016**, *54*, 1.30.1–1.30.33. [[CrossRef](#)] [[PubMed](#)]
42. Szklarczyk, D.; Gable, A.L.; Lyon, D.; Junge, A.; Wyder, S.; Huerta-Cepas, J.; Simonovic, M.; Doncheva, N.T.; Morris, J.H.; Bork, P.; et al. String v11: Protein–protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. *Nucleic Acids Res.* **2019**, *47*, D607–D613. [[CrossRef](#)] [[PubMed](#)]
43. Wickham, H. *Ggplot2: Elegant Graphics for Data Analysis*; Springer: New York, NY, USA, 2016.
44. Kolde, R. Pheatmap: Pretty Heatmaps. R Package Version 1.0.12. Available online: <https://CRAN.R-project.org/package=pheatmap> (accessed on 25 May 2023).
45. Wickham, H. Reshaping Data with the reshapePackage. *J. Stat. Softw.* **2007**, *21*, 1–20. [[CrossRef](#)]
46. Dey, N.; Das, F.; Mariappan, M.M.; Mandal, C.C.; Ghosh-Choudhury, N.; Kasinath, B.S.; Choudhury, G.G. MicroRNA-21 Orchestrates High Glucose-induced Signals to TOR Complex 1, Resulting in Renal Cell Pathology in Diabetes. *J. Biol. Chem.* **2011**, *286*, 25586–25603. [[CrossRef](#)]
47. Zhong, X.; Chung, A.C.K.; Chen, H.Y.; Dong, Y.; Meng, X.M.; Li, R.; Yang, W.; Hou, F.F.; Lan, H.Y. miR-21 is a key therapeutic target for renal injury in a mouse model of type 2 diabetes. *Diabetologia* **2013**, *56*, 663–674. [[CrossRef](#)]
48. Zhang, Z.; Peng, H.; Chen, J.; Chen, X.; Han, F.; Xu, X.; He, X.; Yan, N. MicroRNA-21 protects from mesangial cell proliferation induced by diabetic nephropathy in db/db mice. *FEBS Lett.* **2009**, *583*, 2009–2014. [[CrossRef](#)]
49. Jones, T.F.; Bekele, S.; O’Dwyer, M.J.; Prowle, J.R. MicroRNAs in Acute Kidney Injury. *Nephron* **2018**, *140*, 124–128. [[CrossRef](#)]
50. Krupa, A.; Jenkins, R.; Luo, D.D.; Lewis, A.; Phillips, A.; Fraser, D. Loss of MicroRNA-192 Promotes Fibrogenesis in Diabetic Nephropathy. *J. Am. Soc. Nephrol.* **2010**, *21*, 438–447. [[CrossRef](#)]
51. Wang, B.; Herman-Edelstein, M.; Koh, P.; Burns, W.; Jandeleit-Dahm, K.; Watson, A.; Saleem, M.; Goodall, G.J.; Twigg, S.M.; Cooper, M.E.; et al. E-Cadherin Expression Is Regulated by miR-192/215 by a Mechanism That Is Independent of the Profibrotic Effects of Transforming Growth Factor- β . *Diabetes* **2010**, *59*, 1794–1802. [[CrossRef](#)]
52. Müller-Deile, J.; Dannenberg, J.; Schroder, P.; Lin, M.-H.; Miner, J.H.; Chen, R.; Bräsen, J.-H.; Thum, T.; Nyström, J.; Staggs, L.B.; et al. Podocytes regulate the glomerular basement membrane protein nephronectin by means of miR-378a-3p in glomerular diseases. *Kidney Int.* **2017**, *92*, 836–849. [[CrossRef](#)]
53. Song, L.; Feng, S.; Yu, H.; Shi, S. Dexmedetomidine Protects Against Kidney Fibrosis in Diabetic Mice by Targeting miR-101-3p-Mediated EndMT. *Dose Response* **2022**, *20*, 15593258221083486. [[CrossRef](#)]
54. Scian, M.J.; Maluf, D.G.; David, K.G.; Archer, K.J.; Suh, J.L.; Wolen, A.R.; Mba, M.U.; Massey, H.D.; King, A.L.; Gehr, T.; et al. MicroRNA Profiles in Allograft Tissues and Paired Urines Associate With Chronic Allograft Dysfunction With IF/TA. *Am. J. Transplant.* **2011**, *11*, 2110–2122. [[CrossRef](#)]
55. Zhou, X.; Qu, Z.; Zhu, C.; Lin, Z.; Huo, Y.; Wang, X.; Wang, J.; Li, B. Identification of urinary microRNA biomarkers for detection of gentamicin-induced acute kidney injury in rats. *Regul. Toxicol. Pharmacol.* **2016**, *78*, 78–84. [[CrossRef](#)]
56. Gao, Y.; Xu, W.; Guo, C.; Huang, T. GATA1 regulates the microRNA-328-3p/PIM1 axis via circular RNA ITGB1 to promote renal ischemia/reperfusion injury in HK-2 cells. *Int. J. Mol. Med.* **2022**, *50*, 100. [[CrossRef](#)]
57. Han, X.; Li, Q.; Wang, C.; Li, Y. MicroRNA-204-3p Attenuates High Glucose-Induced MPC5 Podocytes Apoptosis by Targeting Bradykinin B2 Receptor. *Exp. Clin. Endocrinol. Diabetes* **2019**, *127*, 387–395. [[CrossRef](#)]
58. Wang, F.; Zhang, F.; Tian, Q.; Sheng, K. CircVMA21 ameliorates lipopolysaccharide (LPS)-induced HK-2 cell injury depending on the regulation of miR-7-5p/PPARA. *Autoimmunity* **2021**, *55*, 136–146. [[CrossRef](#)]
59. Ghai, V.; Wu, X.; Bheda-Malge, A.; Argyropoulos, C.P.; Bernardo, J.F.; Orchard, T.; Galas, D.; Wang, K. Genome-wide Profiling of Urinary Extracellular Vesicle microRNAs Associated With Diabetic Nephropathy in Type 1 Diabetes. *Kidney Int. Rep.* **2017**, *3*, 555–572. [[CrossRef](#)]
60. Shin, Y.; Kim, D.Y.; Ko, J.Y.; Woo, Y.M.; Park, J.H. Regulation of KLF12 by microRNA-20b and microRNA-106a in cystogenesis. *FASEB J.* **2018**, *32*, 3574–3582. [[CrossRef](#)]
61. Yu, L.; Gu, T.; Shi, E.; Wang, Y.; Fang, Q.; Wang, C. Dysregulation of renal microRNA expression after deep hypothermic circulatory arrest in rats. *Eur. J. Cardiothorac. Surg.* **2016**, *49*, 1725–1731. [[CrossRef](#)]
62. Pavkovic, M.; Vaidya, V.S. MicroRNAs and drug-induced kidney injury. *Pharmacol. Ther.* **2016**, *163*, 48–57. [[CrossRef](#)]
63. Trevisani, F.; Ghidini, M.; Larcher, A.; Lampis, A.; Lote, H.; Manunta, P.; Alibrandi, M.T.S.; Zagato, L.; Citterio, L.; Dell’Antonio, G.; et al. MicroRNA 193b-3p as a predictive biomarker of chronic kidney disease in patients undergoing radical nephrectomy for renal cell carcinoma. *Br. J. Cancer* **2016**, *115*, 1343–1350. [[CrossRef](#)] [[PubMed](#)]
64. Li, X.; Dong, Z.-Q.; Chang, H.; Zhou, H.-B.; Wang, J.; Yang, Z.-J.; Qiu, M.; Bai, W.-F.; Shi, S.-L. Screening and identification of key microRNAs and regulatory pathways associated with the renal fibrosis process. *Mol. Omics* **2022**, *18*, 520–533. [[CrossRef](#)] [[PubMed](#)]

65. He, X.; Zeng, X. LncRNA SNHG16 Aggravates High Glucose-Induced Podocytes Injury in Diabetic Nephropathy Through Targeting miR-106a and Thereby Up-Regulating KLF9. *Diabetes Metab. Syndr. Obes.* **2020**, *13*, 3551–3560. [[CrossRef](#)] [[PubMed](#)]
66. Yu, Y.; Jia, Y.-Y.; Wang, M.; Mu, L.; Li, H.-J. PTGER3 and MMP-2 play potential roles in diabetic nephropathy via competing endogenous RNA mechanisms. *BMC Nephrol.* **2021**, *22*, 27. [[CrossRef](#)]
67. Bijkerk, R.; de Bruin, R.G.; van Solingen, C.; van Gils, J.M.; Duijs, J.M.; van der Veer, E.P.; Rabelink, T.J.; Humphreys, B.D.; van Zonneveld, A.J. Silencing of microRNA-132 reduces renal fibrosis by selectively inhibiting myofibroblast proliferation. *Kidney Int.* **2016**, *89*, 1268–1280. [[CrossRef](#)]
68. Zhang, J.; Zhu, Y.; Cai, R.; Jin, J.; He, Q. Differential Expression of Urinary Exosomal Small RNAs in Idiopathic Membranous Nephropathy. *BioMed Res. Int.* **2020**, *2020*, 3170927. [[CrossRef](#)]
69. Miller, D.; Eagle-Hemming, B.; Sheikh, S.; Joel-David, L.; Adebayo, A.; Lai, F.Y.; Roman, M.; Kumar, T.; Aujla, H.; Murphy, G.J.; et al. Urinary extracellular vesicles and micro-RNA as markers of acute kidney injury after cardiac surgery. *Sci. Rep.* **2022**, *12*, 10402. [[CrossRef](#)]
70. Hou, Y.; Li, Y.; Wang, Y.; Li, W.; Xiao, Z. Screening and Analysis of Key Genes in miRNA-mRNA Regulatory Network of Membranous Nephropathy. *J. Healthc. Eng.* **2021**, *2021*, 5331948. [[CrossRef](#)]
71. Wang, B.; Jha, J.C.; Hagiwara, S.; McClelland, A.D.; Jandeleit-Dahm, K.; Thomas, M.C.; Cooper, M.E.; Kantharidis, P. Transforming growth factor- β 1-mediated renal fibrosis is dependent on the regulation of transforming growth factor receptor 1 expression by let-7b. *Kidney Int.* **2014**, *85*, 352–361. [[CrossRef](#)]
72. Tsai, Y.-C.; Kuo, M.-C.; Hung, W.-W.; Wu, L.-Y.; Wu, P.-H.; Chang, W.-A.; Kuo, P.-L.; Hsu, Y.-L. High Glucose Induces Mesangial Cell Apoptosis through miR-15b-5p and Promotes Diabetic Nephropathy by Extracellular Vesicle Delivery. *Mol. Ther.* **2020**, *28*, 963–974. [[CrossRef](#)]
73. Duan, Y.; Chen, B.; Chen, F.; Yang, S.; Zhu, C.; Ma, Y.; Li, Y.; Shi, J. Exosomal microRNA-16-5p from human urine-derived stem cells ameliorates diabetic nephropathy through protection of podocyte. *J. Cell. Mol. Med.* **2019**, *25*, 10798–10813. [[CrossRef](#)]
74. Wang, X.; Lin, B.; Nie, L.; Li, P. microRNA-20b contributes to high glucose-induced podocyte apoptosis by targeting SIRT7. *Mol. Med. Rep.* **2017**, *16*, 5667–5674. [[CrossRef](#)]
75. Wang, J.-Y.; Gao, Y.-B.; Zhang, N.; Zou, D.-W.; Wang, P.; Zhu, Z.-Y.; Li, J.-Y.; Zhou, S.-N.; Wang, S.-C.; Wang, Y.-Y.; et al. miR-21 overexpression enhances TGF- β 1-induced epithelial-to-mesenchymal transition by target smad7 and aggravates renal damage in diabetic nephropathy. *Mol. Cell. Endocrinol.* **2014**, *392*, 163–172. [[CrossRef](#)]
76. Lai, J.Y.; Luo, J.; O’connor, C.; Jing, X.; Nair, V.; Ju, W.; Randolph, A.; Ben-Dov, I.Z.; Matar, R.N.; Briskin, D.; et al. MicroRNA-21 in Glomerular Injury. *J. Am. Soc. Nephrol.* **2015**, *26*, 805–816. [[CrossRef](#)]
77. Wang, J.; Duan, L.; Tian, L.; Liu, J.; Wang, S.; Gao, Y.; Yang, J. Serum miR-21 may be a Potential Diagnostic Biomarker for Diabetic Nephropathy. *Exp. Clin. Endocrinol. Diabetes* **2016**, *124*, 417–423. [[CrossRef](#)]
78. Kölling, M.; Kaucsar, T.; Schauerte, C.; Hübner, A.; Dettling, A.; Park, J.-K.; Busch, M.; Wulff, X.; Meier, M.; Scherf, K.; et al. Therapeutic miR-21 Silencing Ameliorates Diabetic Kidney Disease in Mice. *Mol. Ther.* **2016**, *25*, 165–180. [[CrossRef](#)]
79. McClelland, A.D.; Herman-Edelstein, M.; Komers, R.; Jha, J.C.; Winbanks, C.E.; Hagiwara, S.; Gregorevic, P.; Kantharidis, P.; Cooper, M.E. miR-21 promotes renal fibrosis in diabetic nephropathy by targeting PTEN and SMAD7. *Clin. Sci.* **2015**, *129*, 1237–1249. [[CrossRef](#)]
80. Zhang, Y.; Zhao, S.; Wu, D.; Liu, X.; Shi, M.; Wang, Y.; Zhang, F.; Ding, J.; Xiao, Y.; Guo, B. MicroRNA-22 Promotes Renal Tubulointerstitial Fibrosis by Targeting PTEN and Suppressing Autophagy in Diabetic Nephropathy. *J. Diabetes Res.* **2018**, *2018*, 4728645. [[CrossRef](#)]
81. Xu, H.; Sun, F.; Li, X.; Sun, L. Down-regulation of miR-23a inhibits high glucose-induced EMT and renal fibrogenesis by up-regulation of SnoN. *Hum. Cell* **2018**, *31*, 22–32. [[CrossRef](#)]
82. Liu, H.; Wang, X.; Liu, S.; Li, H.; Yuan, X.; Feng, B.; Bai, H.; Zhao, B.; Chu, Y.; Li, H. Effects and mechanism of miR-23b on glucose-mediated epithelial-to-mesenchymal transition in diabetic nephropathy. *Int. J. Biochem. Cell Biol.* **2016**, *70*, 149–160. [[CrossRef](#)]
83. Zhao, B.; Li, H.; Liu, J.; Han, P.; Zhang, C.; Bai, H.; Yuan, X.; Wang, X.; Li, L.; Ma, H.; et al. MicroRNA-23b Targets Ras GTPase-Activating Protein SH3 Domain-Binding Protein 2 to Alleviate Fibrosis and Albuminuria in Diabetic Nephropathy. *J. Am. Soc. Nephrol.* **2016**, *27*, 2597–2608. [[CrossRef](#)] [[PubMed](#)]
84. Fu, Y.; Zhang, Y.; Wang, Z.; Wang, L.; Wei, X.; Zhang, B.; Wen, Z.; Fang, H.; Pang, Q.; Yi, F. Regulation of NADPH Oxidase Activity Is Associated with miRNA-25-Mediated NOX4 Expression in Experimental Diabetic Nephropathy. *Am. J. Nephrol.* **2010**, *32*, 581–589. [[CrossRef](#)] [[PubMed](#)]
85. Oh, H.J.; Kato, M.; Deshpande, S.; Zhang, E.; Das, S.; Lanting, L.; Wang, M.; Natarajan, R. Inhibition of the processing of miR-25 by HIPK2-Phosphorylated-MeCP2 induces NOX4 in early diabetic nephropathy. *Sci. Rep.* **2016**, *6*, 38789. [[CrossRef](#)] [[PubMed](#)]
86. Li, H.; Zhu, X.; Zhang, J.; Shi, J. MicroRNA-25 inhibits high glucose-induced apoptosis in renal tubular epithelial cells via PTEN/AKT pathway. *Biomed. Pharmacother.* **2017**, *96*, 471–479. [[CrossRef](#)]
87. Liu, Y.; Li, H.; Liu, J.; Han, P.; Li, X.; Bai, H.; Zhang, C.; Sun, X.; Teng, Y.; Zhang, Y.; et al. Variations in MicroRNA-25 Expression Influence the Severity of Diabetic Kidney Disease. *J. Am. Soc. Nephrol.* **2017**, *28*, 3627–3638. [[CrossRef](#)]
88. Koga, K.; Yokoi, H.; Mori, K.; Kasahara, M.; Kuwabara, T.; Imamaki, H.; Ishii, A.; Mori, K.P.; Kato, Y.; Ohno, S.; et al. MicroRNA-26a inhibits TGF- β -induced extracellular matrix protein expression in podocytes by targeting CTGF and is downregulated in diabetic nephropathy. *Diabetologia* **2015**, *58*, 2169–2180. [[CrossRef](#)]

89. Wu, L.; Wang, Q.; Guo, F.; Ma, X.; Ji, H.; Liu, F.; Zhao, Y.; Qin, G. MicroRNA-27a Induces Mesangial Cell Injury by Targeting of PPAR γ and its In Vivo Knockdown Prevents Progression of Diabetic Nephropathy. *Sci. Rep.* **2016**, *6*, 26072. [[CrossRef](#)]
90. Zhou, Z.; Wan, J.; Hou, X.; Geng, J.; Li, X.; Bai, X. MicroRNA-27a promotes podocyte injury via PPAR γ -mediated β -catenin activation in diabetic nephropathy. *Cell Death Dis.* **2017**, *8*, e2658. [[CrossRef](#)]
91. Beltrami, C.; Simpson, K.; Jesky, M.; Wonnacott, A.; Carrington, C.; Holmans, P.; Newbury, L.; Jenkins, R.; Ashdown, T.; Dayan, C.; et al. Association of Elevated Urinary miR-126, miR-155, and miR-29b with Diabetic Kidney Disease. *Am. J. Pathol.* **2018**, *188*, 1982–1992. [[CrossRef](#)]
92. Chen, H.-Y.; Zhong, X.; Huang, X.R.; Meng, X.-M.; You, Y.; Chung, A.C.; Lan, H.Y. MicroRNA-29b Inhibits Diabetic Nephropathy in db/db Mice. *Mol. Ther.* **2014**, *22*, 842–853. [[CrossRef](#)]
93. Long, J.; Wang, Y.; Wang, W.; Chang, B.H.J.; Danesh, F.R. MicroRNA-29c Is a Signature MicroRNA under High Glucose Conditions That Targets Sprouty Homolog 1, and Its in Vivo Knockdown Prevents Progression of Diabetic Nephropathy. *J. Biol. Chem.* **2011**, *286*, 11837–11848. [[CrossRef](#)]
94. Lin, C.-L.; Lee, P.-H.; Hsu, Y.-C.; Lei, C.-C.; Ko, J.-Y.; Chuang, P.-C.; Huang, Y.-T.; Wang, S.-Y.; Wu, S.-L.; Chen, Y.-S.; et al. MicroRNA-29a Promotion of Nephritin Acetylation Ameliorates Hyperglycemia-Induced Podocyte Dysfunction. *J. Am. Soc. Nephrol.* **2014**, *25*, 1698–1709. [[CrossRef](#)]
95. Hsu, Y.-C.; Chang, P.-J.; Ho, C.; Huang, Y.-T.; Shih, Y.-H.; Wang, C.-J.; Lin, C.-L. Protective effects of miR-29a on diabetic glomerular dysfunction by modulation of DKK1/Wnt/ β -catenin signaling. *Sci. Rep.* **2016**, *6*, 30575. [[CrossRef](#)]
96. Wang, B.; Komers, R.; Carew, R.; Winbanks, C.E.; Xu, B.; Herman-Edelstein, M.; Koh, P.; Thomas, M.; Jandeleit-Dahm, K.; Gregorevic, P.; et al. Suppression of microRNA-29 Expression by TGF- β 1 Promotes Collagen Expression and Renal Fibrosis. *J. Am. Soc. Nephrol.* **2012**, *23*, 252–265. [[CrossRef](#)]
97. Zhao, D.; Jia, J.; Shao, H. miR-30e targets GLIPR-2 to modulate diabetic nephropathy: In vitro and in vivo experiments. *J. Mol. Endocrinol.* **2017**, *59*, 181–190. [[CrossRef](#)]
98. Liu, W.-T.; Peng, F.-F.; Li, H.-Y.; Chen, X.-W.; Gong, W.-Q.; Chen, W.-J.; Chen, Y.-H.; Li, P.-L.; Li, S.-T.; Xu, Z.-Z.; et al. Metadherin facilitates podocyte apoptosis in diabetic nephropathy. *Cell Death Dis.* **2016**, *7*, e2477. [[CrossRef](#)]
99. Wang, Y.; Liu, Y.; Zhang, L.; Bai, L.; Chen, S.; Wu, H.; Sun, L.; Wang, X. miR-30b-5p modulate renal epithelial-mesenchymal transition in diabetic nephropathy by directly targeting SNAI1. *Biochem. Biophys. Res. Commun.* **2021**, *535*, 12–18. [[CrossRef](#)]
100. Cui, L.; Yu, M.; Cui, X. MiR-30c-5p/ROCK2 axis regulates cell proliferation, apoptosis and EMT via the PI3K/AKT signaling pathway in HG-induced HK-2 cells. *Open Life Sci.* **2020**, *15*, 959–970. [[CrossRef](#)]
101. Zhang, L.; He, S.; Guo, S.; Xie, W.; Xin, R.; Yu, H.; Yang, F.; Qiu, J.; Zhang, D.; Zhou, S.; et al. Down-regulation of miR-34a alleviates mesangial proliferation in vitro and glomerular hypertrophy in early diabetic nephropathy mice by targeting GAS1. *J. Diabetes Complicat.* **2014**, *28*, 259–264. [[CrossRef](#)]
102. Xue, M.; Li, Y.; Hu, F.; Jia, Y.-J.; Zheng, Z.-J.; Wang, L.; Xue, Y.-M. High glucose up-regulates microRNA-34a-5p to aggravate fibrosis by targeting SIRT1 in HK-2 cells. *Biochem. Biophys. Res. Commun.* **2018**, *498*, 38–44. [[CrossRef](#)]
103. Liu, X.-D.; Zhang, L.-Y.; Zhu, T.-C.; Zhang, R.-F.; Wang, S.-L.; Bao, Y. Overexpression of miR-34c inhibits high glucose-induced apoptosis in podocytes by targeting Notch signaling pathways. *Int. J. Clin. Exp. Pathol.* **2015**, *8*, 4525–4534. [[PubMed](#)]
104. Long, J.; Wang, Y.; Wang, W.; Chang, B.H.J.; Danesh, F.R. Identification of MicroRNA-93 as a Novel Regulator of Vascular Endothelial Growth Factor in Hyperglycemic Conditions. *J. Biol. Chem.* **2010**, *285*, 23457–23465. [[CrossRef](#)] [[PubMed](#)]
105. Li, D.; Lu, Z.; Jia, J.; Zheng, Z.; Lin, S. MiR-124 is Related to Podocytic Adhesive Capacity Damage in STZ-Induced Uninephrectomized Diabetic Rats. *Kidney Blood Press. Res.* **2013**, *37*, 422–431. [[CrossRef](#)] [[PubMed](#)]
106. Jiang, Y.; Wang, W.; Liu, Z.; Xie, Y.; Qian, Y.; Cai, X. Overexpression of miR-130a-3p/301a-3p attenuates high glucose-induced MPC5 podocyte dysfunction through suppression of TNF- α signaling. *Exp. Ther. Med.* **2017**, *15*, 1021–1028. [[CrossRef](#)] [[PubMed](#)]
107. Bai, X.; Geng, J.; Zhou, Z.; Tian, J.; Li, X. MicroRNA-130b improves renal tubulointerstitial fibrosis via repression of Snail-induced epithelial-mesenchymal transition in diabetic nephropathy. *Sci. Rep.* **2016**, *6*, 20475. [[CrossRef](#)]
108. Sun, Z.; Ma, Y.; Chen, F.; Wang, S.; Chen, B.; Shi, J. miR-133b and miR-199b knockdown attenuate TGF- β 1-induced epithelial to mesenchymal transition and renal fibrosis by targeting SIRT1 in diabetic nephropathy. *Eur. J. Pharmacol.* **2018**, *837*, 96–104. [[CrossRef](#)]
109. Qian, X.; Tan, J.; Liu, L.; Chen, S.; You, N.; Yong, H.; Pan, M.; You, Q.; Ding, D.; Lu, Y. MicroRNA-134-5p promotes high glucose-induced podocyte apoptosis by targeting bcl-2. *Am. J. Transl. Res.* **2018**, *10*, 989–997.
110. He, F.; Peng, F.; Xia, X.; Zhao, C.; Luo, Q.; Guan, W.; Li, Z.; Yu, X.; Huang, F. MiR-135a promotes renal fibrosis in diabetic nephropathy by regulating TRPC1. *Diabetologia* **2014**, *57*, 1726–1736. [[CrossRef](#)]
111. Su, J.; Ren, J.; Chen, H.; Liu, B. MicroRNA-140-5p ameliorates the high glucose-induced apoptosis and inflammation through suppressing TLR4/NF- κ B signaling pathway in human renal tubular epithelial cells. *Biosci. Rep.* **2020**, *40*, BSR20192384. [[CrossRef](#)]
112. Barutta, F.; Tricarico, M.; Corbelli, A.; Annaratone, L.; Pinach, S.; Grimaldi, S.; Bruno, G.; Cimino, D.; Taverna, D.; Deregibus, M.C.; et al. Urinary Exosomal MicroRNAs in Incipient Diabetic Nephropathy. *PLoS ONE* **2013**, *8*, e73798. [[CrossRef](#)]
113. Wei, B.; Liu, Y.; Guan, H. MicroRNA-145-5p attenuates high glucose-induced apoptosis by targeting the Notch signaling pathway in podocytes. *Exp. Ther. Med.* **2020**, *19*, 1915–1924. [[CrossRef](#)]

114. Huang, Y.; Liu, Y.; Li, L.; Su, B.; Yang, L.; Fan, W.; Yin, Q.; Chen, L.; Cui, T.; Zhang, J.; et al. Involvement of inflammation-related miR-155 and miR-146a in diabetic nephropathy: Implications for glomerular endothelial injury. *BMC Nephrol.* **2014**, *15*, 142. [[CrossRef](#)]
115. Lee, H.W.; Khan, S.Q.; Khaliqdina, S.; Altintas, M.M.; Grahammer, F.; Zhao, J.L.; Koh, K.H.; Tardi, N.J.; Faridi, M.H.; Geraghty, T.; et al. Absence of miR-146a in Podocytes Increases Risk of Diabetic Glomerulopathy via Up-regulation of ErbB4 and Notch-1. *J. Biol. Chem.* **2017**, *292*, 732–747. [[CrossRef](#)]
116. Bhatt, K.; Lanting, L.L.; Jia, Y.; Yadav, S.; Reddy, M.A.; Magilnick, N.; Boldin, M.; Natarajan, R. Anti-Inflammatory Role of MicroRNA-146a in the Pathogenesis of Diabetic Nephropathy. *J. Am. Soc. Nephrol.* **2016**, *27*, 2277–2288. [[CrossRef](#)]
117. Wan, R.J.; Li, Y.H. MicroRNA-146a/NAPDH oxidase4 decreases reactive oxygen species generation and inflammation in a diabetic nephropathy model. *Mol. Med. Rep.* **2018**, *17*, 4759–4766. [[CrossRef](#)]
118. Wang, Y.; Zheng, Z.-J.; Jia, Y.-J.; Yang, Y.-L.; Xue, Y.-M. Role of p53/miR-155-5p/sirt1 loop in renal tubular injury of diabetic kidney disease. *J. Transl. Med.* **2018**, *16*, 146. [[CrossRef](#)]
119. Xu, P.; Guan, M.-P.; Bi, J.-G.; Wang, D.; Zheng, Z.; Xue, Y.-M. High glucose down-regulates microRNA-181a-5p to increase pro-fibrotic gene expression by targeting early growth response factor 1 in HK-2 cells. *Cell. Signal.* **2017**, *31*, 96–104. [[CrossRef](#)]
120. Kato, M.; Zhang, J.; Wang, M.; Lanting, L.; Yuan, H.; Rossi, J.J.; Natarajan, R. MicroRNA-192 in diabetic kidney glomeruli and its function in TGF-beta-induced collagen expression via inhibition of E-box repressors. *Proc. Natl. Acad. Sci. USA* **2007**, *104*, 3432–3437. [[CrossRef](#)]
121. Kato, M.; Arce, L.; Wang, M.; Putta, S.; Lanting, L.; Natarajan, R. A microRNA circuit mediates transforming growth factor- β 1 autoregulation in renal glomerular mesangial cells. *Kidney Int.* **2011**, *80*, 358–368. [[CrossRef](#)]
122. Deshpande, S.D.; Putta, S.; Wang, M.; Lai, J.Y.; Bitzer, M.; Nelson, R.G.; Lanting, L.L.; Kato, M.; Natarajan, R. Transforming Growth Factor- β -Induced Cross Talk Between p53 and a MicroRNA in the Pathogenesis of Diabetic Nephropathy. *Diabetes* **2013**, *62*, 3151–3162. [[CrossRef](#)]
123. Mishra, A.; Ayasolla, K.; Kumar, V.; Lan, X.; Vashistha, H.; Aslam, R.; Hussain, A.; Chowdhary, S.; Shoshtari, S.M.; Paliwal, N.; et al. Modulation of apolipoprotein L1-microRNA-193a axis prevents podocyte dedifferentiation in high-glucose milieu. *Am. J. Physiol. Physiol.* **2018**, *314*, F832–F843. [[CrossRef](#)] [[PubMed](#)]
124. Chen, Y.Q.; Wang, X.X.; Yao, X.M.; Zhang, D.L.; Yang, X.F.; Tian, S.F.; Wang, N.S. Abated microRNA-195 expression protected mesangial cells from apoptosis in early diabetic renal injury in mice. *J. Nephrol.* **2011**, *25*, 566–576. [[CrossRef](#)] [[PubMed](#)]
125. Wang, X.; Shen, E.; Wang, Y.; Jiang, Z.; Gui, D.; Cheng, D.; Chen, T.; Wang, N. MiR-196a Regulates High Glucose-Induced Mesangial Cell Hypertrophy by Targeting p27kip1. *SLAS Technol. Transl. Life Sci. Innov.* **2015**, *20*, 491–499. [[CrossRef](#)] [[PubMed](#)]
126. Zhang, R.; Qin, L.; Shi, J. MicroRNA-199a-3p suppresses high glucose-induced apoptosis and inflammation by regulating the IKK β /NF- κ B signaling pathway in renal tubular epithelial cells. *Int. J. Mol. Med.* **2020**, *46*, 2161–2171. [[CrossRef](#)]
127. Wang, B.; Koh, P.; Winbanks, C.; Coughlan, M.T.; McClelland, A.; Watson, A.; Jandeleit-Dahm, K.; Burns, W.C.; Thomas, M.C.; Cooper, M.E.; et al. miR-200a Prevents Renal Fibrogenesis Through Repression of TGF- β 2 Expression. *Diabetes* **2010**, *60*, 280–287. [[CrossRef](#)]
128. Park, J.T.; Kato, M.; Yuan, H.; Castro, N.; Lanting, L.; Wang, M.; Natarajan, R. FOG2 Protein Down-regulation by Transforming Growth Factor- β 1-induced MicroRNA-200b/c Leads to Akt Kinase Activation and Glomerular Mesangial Hypertrophy Related to Diabetic Nephropathy. *J. Biol. Chem.* **2013**, *288*, 22469–22480. [[CrossRef](#)]
129. Wang, X.; Shen, E.; Wang, Y.; Li, J.; Cheng, D.; Chen, Y.; Gui, D.; Wang, N. Cross talk between miR-214 and PTEN attenuates glomerular hypertrophy under diabetic conditions. *Sci. Rep.* **2016**, *6*, 31506. [[CrossRef](#)]
130. Bera, A.; Das, F.; Ghosh-Choudhury, N.; Mariappan, M.M.; Kasinath, B.S.; Choudhury, G.G. Reciprocal regulation of miR-214 and PTEN by high glucose regulates renal glomerular mesangial and proximal tubular epithelial cell hypertrophy and matrix expansion. *Am. J. Physiol. Physiol.* **2017**, *313*, C430–C447. [[CrossRef](#)]
131. Kato, M.; Putta, S.; Wang, M.; Yuan, H.; Lanting, L.; Nair, I.; Gunn, A.; Nakagawa, Y.; Shimano, H.; Todorov, I.; et al. TGF- β activates Akt kinase through a microRNA-dependent amplifying circuit targeting PTEN. *Nature* **2009**, *11*, 881–889. [[CrossRef](#)]
132. Kato, M.; Wang, L.; Putta, S.; Wang, M.; Yuan, H.; Sun, G.; Lanting, L.; Todorov, I.; Rossi, J.J.; Natarajan, R. Post-transcriptional Up-regulation of Tsc-22 by Ybx1, a Target of miR-216a, Mediates TGF- β -induced Collagen Expression in Kidney Cells*. *J. Biol. Chem.* **2010**, *285*, 34004–34015. [[CrossRef](#)]
133. Sun, J.; Li, Z.P.; Zhang, R.Q.; Zhang, H.M. Repression of miR-217 protects against high glucose-induced podocyte injury and insulin resistance by restoring PTEN-mediated autophagy pathway. *Biochem. Biophys. Res. Commun.* **2017**, *483*, 318–324. [[CrossRef](#)]
134. Yang, H.; Wang, Q.; Li, S. MicroRNA-218 promotes high glucose-induced apoptosis in podocytes by targeting heme oxygenase-1. *Biochem. Biophys. Res. Commun.* **2016**, *471*, 582–588. [[CrossRef](#)]
135. Jiang, Z.; Tang, Y.; Song, H.; Yang, M.; Li, B.; Ni, C. miRNA-342 suppresses renal interstitial fibrosis in diabetic nephropathy by targeting SOX6. *Int. J. Mol. Med.* **2019**, *45*, 45–52. [[CrossRef](#)]
136. Yang, Z.; Guo, Z.; Dong, J.; Sheng, S.; Wang, Y.; Yu, L.; Wang, H.; Tang, L. miR-374a Regulates Inflammatory Response in Diabetic Nephropathy by Targeting MCP-1 Expression. *Front. Pharmacol.* **2018**, *9*, 900. [[CrossRef](#)]
137. Wang, Q.; Wang, Y.; Minto, A.W.; Wang, J.; Shi, Q.; Li, X.; Quigg, R.J. MicroRNA-377 is up-regulated and can lead to increased fibronectin production in diabetic nephropathy. *FASEB J.* **2008**, *22*, 4126–4135. [[CrossRef](#)]

138. Li, N.; Wang, L.; Xu, W.; Liu, S.; Yu, J. MicroRNA-379-5p suppresses renal fibrosis by regulating the LIN28/let-7 axis in diabetic nephropathy. *Int. J. Mol. Med.* **2019**, *44*, 1619–1628. [[CrossRef](#)]
139. Kato, M.; Wang, M.; Chen, Z.; Bhatt, K.; Oh, H.J.; Lanting, L.; Deshpande, S.; Jia, Y.; Lai, J.Y.; O’connor, C.L.; et al. An endoplasmic reticulum stress-regulated lncRNA hosting a microRNA megacluster induces early features of diabetic nephropathy. *Nat. Commun.* **2016**, *7*, 12864. [[CrossRef](#)]
140. Xu, Y.; Zhang, J.; Fan, L.; He, X. miR-423-5p suppresses high-glucose-induced podocyte injury by targeting Nox4. *Biochem. Biophys. Res. Commun.* **2018**, *505*, 339–345. [[CrossRef](#)]
141. Sun, Y.; Peng, R.; Peng, H.; Liu, H.; Wen, L.; Wu, T.; Yi, H.; Li, A.; Zhang, Z. miR-451 suppresses the NF-kappaB-mediated proinflammatory molecules expression through inhibiting LMP7 in diabetic nephropathy. *Mol. Cell. Endocrinol.* **2016**, *433*, 75–86. [[CrossRef](#)]
142. Mohan, A.; Singh, R.S.; Kumari, M.; Garg, D.; Upadhyay, A.; Ecelbarger, C.M.; Tripathy, S.; Tiwari, S. Urinary Exosomal microRNA-451-5p Is a Potential Early Biomarker of Diabetic Nephropathy in Rats. *PLoS ONE* **2016**, *11*, e0154055. [[CrossRef](#)]
143. Zha, F.; Bai, L.; Tang, B.; Li, J.; Wang, Y.; Zheng, P.; Ji, T.; Bai, S. MicroRNA-503 contributes to podocyte injury via targeting E2F3 in diabetic nephropathy. *J. Cell. Biochem.* **2019**, *120*, 12574–12581. [[CrossRef](#)] [[PubMed](#)]
144. Wang, L.; Li, H. MiR-770-5p facilitates podocyte apoptosis and inflammation in diabetic nephropathy by targeting TIMP3. *Biosci. Rep.* **2020**, *40*, BSR20193653. [[CrossRef](#)] [[PubMed](#)]
145. Zanchi, C.; Macconi, D.; Trionfini, P.; Tomasoni, S.; Rottoli, D.; Locatelli, M.; Rudnicki, M.; Vandesompele, J.; Mestdagh, P.; Remuzzi, G.; et al. MicroRNA-184 is a downstream effector of albuminuria driving renal fibrosis in rats with diabetic nephropathy. *Diabetologia* **2017**, *60*, 1114–1125. [[CrossRef](#)] [[PubMed](#)]
146. Yao, T.; Zha, D.; Gao, P.; Shui, H.; Wu, X. MiR-874 alleviates renal injury and inflammatory response in diabetic nephropathy through targeting toll-like receptor-4. *J. Cell. Physiol.* **2018**, *234*, 871–879. [[CrossRef](#)] [[PubMed](#)]
147. Alvarez, M.L.; Khosroheidari, M.; Eddy, E.; Kiefer, J. Role of MicroRNA 1207-5P and Its Host Gene, the Long Non-Coding RNA Pvt1, as Mediators of Extracellular Matrix Accumulation in the Kidney: Implications for Diabetic Nephropathy. *PLoS ONE* **2013**, *8*, e77468. [[CrossRef](#)]
148. Argyropoulos, C.; Wang, K.; McClarty, S.; Huang, D.; Bernardo, J.; Ellis, D.; Orchard, T.; Galas, D.; Johnson, J. Urinary MicroRNA Profiling in the Nephropathy of Type 1 Diabetes. *PLoS ONE* **2013**, *8*, e54662. [[CrossRef](#)]
149. Wang, G.; Kwan, B.C.-H.; Lai, F.M.-M.; Chow, K.-M.; Li, P.K.-T.; Szeto, C.-C. Urinary sediment miRNA levels in adult nephrotic syndrome. *Clin. Chim. Acta* **2013**, *418*, 5–11. [[CrossRef](#)]
150. Liu, Y.; Gao, G.; Yang, C.; Zhou, K.; Shen, B.; Liang, H.; Jiang, X. Stability of miR-126 in Urine and Its Potential as a Biomarker for Renal Endothelial Injury with Diabetic Nephropathy. *Int. J. Endocrinol.* **2014**, *2014*, 393109. [[CrossRef](#)]
151. Delić, D.; Eisele, C.; Schmid, R.; Baum, P.; Wiech, F.; Gerl, M.; Zimdahl, H.; Pullen, S.S.; Urquhart, R. Urinary Exosomal miRNA Signature in Type II Diabetic Nephropathy Patients. *PLoS ONE* **2016**, *11*, e0150154. [[CrossRef](#)]
152. Eissa, S.; Matboli, M.; Aboushahba, R.; Bekhet, M.M.; Soliman, Y. Urinary exosomal microRNA panel unravels novel biomarkers for diagnosis of type 2 diabetic kidney disease. *J. Diabetes Complicat.* **2016**, *30*, 1585–1592. [[CrossRef](#)]
153. Xie, Y.; Jia, Y.; Cuihua, X.; Hu, F.; Xue, M.; Xue, Y. Urinary Exosomal MicroRNA Profiling in Incipient Type 2 Diabetic Kidney Disease. *J. Diabetes Res.* **2017**, *2017*, 6978984. [[CrossRef](#)]
154. Dieter, C.; Assmann, T.S.; Costa, A.R.; Canani, L.H.; De Souza, B.M.; Bauer, A.C.; Crispim, D. MiR-30e-5p and MiR-15a-5p Expressions in Plasma and Urine of Type 1 Diabetic Patients With Diabetic Kidney Disease. *Front. Genet.* **2019**, *10*, 563. [[CrossRef](#)]
155. Conserva, F.; Barozzino, M.; Pesce, F.; Divella, C.; Oranger, A.; Papale, M.; Sallustio, F.; Simone, S.; Laviola, L.; Giorgino, F.; et al. Urinary miRNA-27b-3p and miRNA-1228-3p correlate with the progression of Kidney Fibrosis in Diabetic Nephropathy. *Sci. Rep.* **2019**, *9*, 11357. [[CrossRef](#)]
156. Park, S.; Kim, O.-H.; Lee, K.; Park, I.B.; Kim, N.H.; Moon, S.; Im, J.; Sharma, S.P.; Oh, B.-C.; Nam, S.; et al. Plasma and urinary extracellular vesicle microRNAs and their related pathways in diabetic kidney disease. *Genomics* **2022**, *114*, 110407. [[CrossRef](#)]
157. Li, Y.; Song, Y.-H.; Li, F.; Yang, T.; Lu, Y.W.; Geng, Y.-J. microRNA-221 regulates high glucose-induced endothelial dysfunction. *Biochem. Biophys. Res. Commun.* **2009**, *381*, 81–83. [[CrossRef](#)]
158. Liu, Y.; Liu, B.; Liu, Y.; Chen, S.; Yang, J.; Liu, J.; Sun, G.; Bei, W.-J.; Wang, K.; Chen, Z.; et al. MicroRNA expression profile by next-generation sequencing in a novel rat model of contrast-induced acute kidney injury. *Ann. Transl. Med.* **2019**, *7*, 178. [[CrossRef](#)]
159. Raigorodskaya, M.P.; Zhiyanov, A.P.; Averinskaya, D.A.; Tonevitsky, E.A. Changes in the Expression of miRNA Isoforms and Their Targets in HT-29 Cells after Hypoxic Exposure. *Bull. Exp. Biol. Med.* **2022**, *173*, 123–127. [[CrossRef](#)]
160. Min, K.-H.; Yang, W.-M.; Lee, W. Saturated fatty acids-induced miR-424-5p aggravates insulin resistance via targeting insulin receptor in hepatocytes. *Biochem. Biophys. Res. Commun.* **2018**, *503*, 1587–1593. [[CrossRef](#)]
161. Baker, M.A.; Davis, S.J.; Liu, P.; Pan, X.; Williams, A.M.; Iczkowski, K.A.; Gallagher, S.T.; Bishop, K.; Regner, K.R.; Liu, Y.; et al. Tissue-Specific MicroRNA Expression Patterns in Four Types of Kidney Disease. *J. Am. Soc. Nephrol.* **2017**, *28*, 2985–2992. [[CrossRef](#)]
162. Bai, X.-Y.; Ma, Y.; Ding, R.; Fu, B.; Shi, S.; Chen, X.-M. miR-335 and miR-34a Promote Renal Senescence by Suppressing Mitochondrial Antioxidative Enzymes. *J. Am. Soc. Nephrol.* **2011**, *22*, 1252–1261. [[CrossRef](#)]

163. Agudiez, M.; Martinez, P.J.; Martin-Lorenzo, M.; Heredero, A.; Santiago-Hernandez, A.; Molero, D.; Garcia-Segura, J.M.; Aldamiz-Echevarria, G.; Alvarez-Llamas, G. Analysis of urinary exosomal metabolites identifies cardiovascular risk signatures with added value to urine analysis. *BMC Biol.* **2020**, *18*, 192. [[CrossRef](#)] [[PubMed](#)]
164. Zhu, Q.; Li, H.; Ao, Z.; Xu, H.; Luo, J.; Kaurich, C.; Yang, R.; Zhu, P.-W.; Chen, S.-D.; Wang, X.-D.; et al. Lipidomic identification of urinary extracellular vesicles for non-alcoholic steatohepatitis diagnosis. *J. Nanobiotechnol.* **2022**, *20*, 349. [[CrossRef](#)] [[PubMed](#)]
165. Oosthuyzen, W.; Sime, N.E.L.; Ivy, J.R.; Turtle, E.J.; Street, J.M.; Pound, J.; Bath, L.E.; Webb, D.J.; Gregory, C.D.; Bailey, M.; et al. Quantification of human urinary exosomes by nanoparticle tracking analysis. *J. Physiol.* **2013**, *591*, 5833–5842. [[CrossRef](#)] [[PubMed](#)]
166. Zhou, H.; Yuen, P.; Pisitkun, T.; Gonzales, P.; Yasuda, H.; Dear, J.; Gross, P.; Knepper, M.; Star, R. Collection, storage, preservation, and normalization of human urinary exosomes for biomarker discovery. *Kidney Int.* **2006**, *69*, 1471–1476. [[CrossRef](#)]
167. Hogan, M.C.; Lieske, J.C.; Lienczewski, C.C.; Nesbitt, L.L.; Wickman, L.T.; Heyer, C.M.; Harris, P.C.; Ward, C.J.; Sundsbak, J.L.; Manganelli, L.; et al. Strategy and rationale for urine collection protocols employed in the NEPTUNE study. *BMC Nephrol.* **2015**, *16*, 190. [[CrossRef](#)]
168. Armstrong, D.A.; Dessaint, J.A.; Ringelberg, C.S.; Hazlett, H.F.; Howard, L.; Abdalla, M.A.; Barnaby, R.L.; Stanton, B.A.; Cervinski, M.A.; Ashare, A. Pre-Analytical Handling Conditions and Small RNA Recovery from Urine for miRNA Profiling. *J. Mol. Diagn.* **2018**, *20*, 565–571. [[CrossRef](#)]
169. Vago, R.; Radano, G.; Zocco, D.; Zarovni, N. Urine stabilization and normalization strategies favor unbiased analysis of urinary EV content. *Sci. Rep.* **2022**, *12*, 17663. [[CrossRef](#)]
170. Abbas-Aghababazadeh, F.; Li, Q.; Fridley, B.L. Comparison of normalization approaches for gene expression studies completed with high-throughput sequencing. *PLoS ONE* **2018**, *13*, e0206312. [[CrossRef](#)]
171. Royo, F.; Théry, C.; Falcón-Pérez, J.M.; Nieuwland, R.; Witwer, K.W. Methods for Separation and Characterization of Extracellular Vesicles: Results of a Worldwide Survey Performed by the ISEV Rigor and Standardization Subcommittee. *Cells* **2020**, *9*, 1955. [[CrossRef](#)]
172. Sáenz-Cuesta, M.; Arbelaiz, A.; Oregi, A.; Irizar, H.; Osorio-Querejeta, I.; Muñoz-Culla, M.; Banales, J.; Falcón-Pérez, J.M.; Olascoaga, J.; Otaegui, D. Methods for extracellular vesicles isolation in a hospital setting. *Front. Immunol.* **2015**, *6*, 50. [[CrossRef](#)]
173. Van Deun, J.; Mestdagh, P.; Agostinis, P.; Akay, Ö.; Anand, S.; Anckaert, J.; Martinez, Z.A.; Baetens, T.; Beghein, E.; Bertier, L.; et al. EV-TRACK: Transparent reporting and centralizing knowledge in extracellular vesicle research. *Nat. Methods* **2017**, *14*, 228–232. [[CrossRef](#)]
174. Yekula, A.; Muralidharan, K.; Kang, K.M.; Wang, L.; Balaj, L.; Carter, B.S. From laboratory to clinic: Translation of extracellular vesicle based cancer biomarkers. *Methods* **2020**, *177*, 58–66. [[CrossRef](#)]
175. Tuttle, K.R.; Agarwal, R.; Alpers, C.E.; Bakris, G.L.; Brosius, F.C.; Kolkhof, P.; Uribarri, J. Molecular mechanisms and therapeutic targets for diabetic kidney disease. *Kidney Int.* **2022**, *102*, 248–260. [[CrossRef](#)]
176. DeFronzo, R.A.; Reeves, W.B.; Awad, A.S. Pathophysiology of diabetic kidney disease: Impact of SGLT2 inhibitors. *Nat. Rev. Nephrol.* **2021**, *17*, 319–334. [[CrossRef](#)]
177. Toth-Manikowski, S.; Atta, M.G. Diabetic Kidney Disease: Pathophysiology and Therapeutic Targets. *J. Diabetes Res.* **2015**, *2015*, 697010. [[CrossRef](#)]
178. Mateescu, B.; Kowal, E.J.K.; Van Balkom, B.W.M.; Bartel, S.; Bhattacharyya, S.N.; Buzás, E.I.; Buck, A.H.; de Candia, P.; Chow, F.W.N.; Das, S.; et al. Obstacles and opportunities in the functional analysis of extracellular vesicle RNA—An ISEV position paper. *J. Extracell. Vesicles* **2017**, *6*, 1286095. [[CrossRef](#)]
179. Chen, Y.; Zhu, Q.; Cheng, L.; Wang, Y.; Li, M.; Yang, Q.; Hu, L.; Lou, D.; Li, J.; Dong, X.; et al. Exosome detection via the ultrafast-isolation system: EXODUS. *Nat. Methods* **2021**, *18*, 212–218. [[CrossRef](#)]
180. Vandesompele, J.; De Preter, K.; Pattyn, F.; Poppe, B.; Van Roy, N.; De Paepe, A.; Speleman, F. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. *Genome Biol.* **2002**, *3*, research0034.1. [[CrossRef](#)]

Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.